<SEC-DOCUMENT>0001193125-24-217618.txt : 20240912
<SEC-HEADER>0001193125-24-217618.hdr.sgml : 20240912
<ACCEPTANCE-DATETIME>20240912064952
ACCESSION NUMBER:		0001193125-24-217618
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240911
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240912
DATE AS OF CHANGE:		20240912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Summit Therapeutics Inc.
		CENTRAL INDEX KEY:			0001599298
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36866
		FILM NUMBER:		241293857

	BUSINESS ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-460-8308

	MAIL ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Therapeutics plc
		DATE OF NAME CHANGE:	20150219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Corp plc
		DATE OF NAME CHANGE:	20140205
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d799002d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:smmt="http://www.summitplc.com/20240911" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-328">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-11_to_2024-09-11">0001599298</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="smmt-20240911.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-11_to_2024-09-11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-11</xbrli:startDate> <xbrli:endDate>2024-09-11</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-339">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt:datemonthdayyearen" id="ixv-340">September 11, 2024</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-341">Summit Therapeutics Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:stateprovnameen" id="ixv-342">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-343">001-36866</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-344">37-1979717</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-345">601 Brickell Key Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-346">Suite 1000</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-347">Miami</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-348">FL</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-349">33131</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-350">(305)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-351">203-2034</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:boolballotbox" id="ixv-352">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Each Exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on Which Registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-356">Common stock, $0.01 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-357">SMMT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:exchnameen" id="ixv-358">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-11_to_2024-09-11" format="ixt-sec:boolballotbox" id="ixv-359">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;11, 2024, Summit Therapeutics Inc. (the &#8220;Company&#8221;) entered into securities purchase agreements (the &#8220;Purchase Agreements&#8221;) with multiple leading biotech institutional and individual accredited investors (the &#8220;Investors&#8221;), for the sale by the Company in a private placement (the &#8220;Private Placement&#8221;) of an aggregate of 10,352,418 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), at purchase price of $22.70 per Share, which was the closing price of the Common Stock on September&#160;11, 2024, for aggregate gross proceeds to the Company of approximately $235.0&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Chief Executive Officer, Executive Chairman and majority stockholder, Robert W. Duggan, Chief Executive Officer, President and member of its Board of Directors (the &#8220;Board&#8221;), Dr.&#160;Mahkam Zanganeh, Chief Operating Officer, Chief Financial Officer and member of the Board, Manmeet Soni, Chief Accounting Officer, Bhaskar Anand, and member of the Board, Jeff Huber, through his controlled entity Caspian Capital LLC, each participated as Investors in the Private Placement, purchasing an aggregate of 3,480,173 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Private Placement is expected to occur on or before September&#160;18, 2024, subject to the satisfaction of certain customary closing conditions. The Purchase Agreements contain customary representations, warranties and covenants by the Company, customary indemnification obligations of the Company, including for liabilities under the Securities Act, as amended (the &#8220;Securities Act&#8221;), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties to such agreements and were subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares issuable pursuant to the Purchase Agreements will not be registered under the Securities Act, and will be issued in reliance on the exemption from registration requirements thereof provided by Section&#160;4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act. The Company relied on these exemptions from registration based in part on representations made by the Investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;11, 2024, in connection with the Purchase Agreements, the Company entered into Registration Rights Agreements with the Investors (the &#8220;Registration Rights Agreements&#8221;). The Registration Rights Agreements provide, among other things, that the Company will as soon as reasonably practicable file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement registering the resale of the Shares. The Company agreed to use its reasonable best efforts to have such registration statement declared effective as soon as practicable after the filing thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Purchase Agreements and the Registration Rights Agreements does not purport to be complete and is qualified in its entirety by reference to the text of the Purchase Agreements and the Registration Rights Agreements, the forms of which are filed as Exhibits 10.1 and 10.2 hereto, respectively, and are incorporated herein by reference. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> regarding the Private Placement is incorporated by reference in this Item&#160;3.02. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2024, the Company issued a press release announcing the Private Placement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statement and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Exhibit</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">No.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="text-decoration:underline">Description</span></span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1<sup style="font-size:75%; vertical-align:top"><span style="font-size:6.5pt">&#8224;</span></sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d799002dex101.htm">Form of Securities Purchase Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2<sup style="font-size:75%; vertical-align:top"><span style="font-size:6.5pt">&#8224;</span></sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d799002dex102.htm">Form of Registration Rights Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d799002dex991.htm">Press Release dated September&#160;12, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(5). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;contains</span> forward-looking statements within the meaning of Section&#160;27A of the&#160;Securities Act of 1933, as amended, and Section&#160;21E of the&#160;Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;suggest,&#8221; &#8220;target,&#8221; &#8220;on track,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;are</span> forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the expected closing date of the Private Placement. These and other risks are described in greater detail under the section titled &#8220;Risk Factors&#8221; contained in the Company&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K&#160;and</span> Quarterly Reports on <span style="white-space:nowrap">Form&#160;10-Q&#160;and</span> the company&#8217;s other filings with the SEC. Any forward-looking statements that the company makes in this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;are</span> made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this Current Report on <span style="white-space:nowrap">Form&#160;8-K.&#160;Except</span> as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">SUMMIT THERAPEUTICS&#160;INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;12, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Manmeet S. Soni</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Operating Officer and Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">(Principal Financial Officer)</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d799002dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECURITIES PURCHASE AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is dated as of September&nbsp;11, 2024, by and among Summit
Therapeutics Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), and each of the entities listed on <U>Exhibit A</U> attached to this Agreement (each, an &#147;<B>Investor</B>&#148; and together, the &#147;<B>Investors</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section&nbsp;4(a)(2) and/or Rule 506 of Regulation D promulgated thereunder of the U.S. Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not
jointly, upon the terms and subject to the conditions stated in this Agreement, shares (the &#147;<B>Shares</B>&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;<B>Common Stock</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the sale of the Shares, the parties hereto will execute and deliver a Registration Rights Agreement,
substantially in the form attached hereto as <U>Exhibit B</U>, pursuant to which the Company will agree to provide certain registration rights in respect of the Shares under the Securities Act and applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and
each Investor, severally and not jointly, agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall
have the following respective meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2024 SEC Reports</B>&#148; means (a)&nbsp;the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 and (b)&nbsp;any Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or any Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed or furnished (as applicable) by the Company after December&nbsp;31, 2023 and prior to the Business Day immediately preceding the date hereof, together in each case with any documents incorporated by
reference therein or exhibits thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that, directly or
indirectly through one or more intermediates, controls, is controlled by or is under common control with such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning set forth in the recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Certificate of Incorporation</B>&#148; means the Certificate of Incorporation of the Company, as currently in
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended and Restated Bylaws</B>&#148; means the Bylaws of the Company, as currently in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Benefit Plan</B>&#148; or &#147;<B>Benefit Plans</B>&#148; means employee benefit
plans as defined in Section&nbsp;3(3) of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for
disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by
the Company or to which the Company or any of its Significant Subsidiaries is obligated to contribute for employees or former employees of the Company and its Significant Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board of Directors</B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> hereof.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock</B>&#148; has the meaning set forth in the recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock Equivalents</B>&#148; means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; has the meaning set forth in the recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Data</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosure Document</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.3</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disqualification Event</B>&#148; has the meaning set forth in Section&nbsp;3.28 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Drug Regulatory Agency</B>&#148; means the U.S. Food and Drug Administration (&#147;<B>FDA</B>&#148;) or other foreign, state, local
or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological
products and drug or biological product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.15</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the U.S. Employee Retirement Income Security Act of 1974,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and
regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financial Statements</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.8(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GDPR</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.34</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authorizations</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.11</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Health Care Laws</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.21</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.33</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.12</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor</B>&#148; and &#147;<B>Investors</B>&#148; have the meanings set forth
in the recitals hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuer Covered Person</B>&#148; has the meaning set forth in <U>Section&nbsp;3.28</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IT Systems</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.33</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Adverse Effect</B>&#148; means any change, event, circumstance, development, condition, occurrence or effect that,
individually or in the aggregate, (a)&nbsp;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#146; equity or results of operations of the Company
and its Significant Subsidiaries, taken as a whole, or (b)&nbsp;materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction
Agreements, or with respect to the Closing or would reasonably be expected to do so; provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be
taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a)&nbsp;of this definition: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any
other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that
the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any change that generally affects industries in which the Company and its
Significant Subsidiaries conduct business, provided that the Company is not disproportionately affected thereby; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) earthquakes,
hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related strains, epidemic or similar health
emergency, and other force majeure events in the United States or any other location, provided that the Company is not disproportionately affected thereby; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) national or international political or social conditions (or changes in such
conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) material changes in laws after the date of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses,
earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in
determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nasdaq</B>&#148; means the Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>National Exchange</B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Per Share Price</B>&#148; means $22.70. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability company, business trust, joint stock company,
trust, unincorporated association, joint venture or any other entity or organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal Data</B>&#148; has the meaning
set forth in <U>Section</U><U></U><U>&nbsp;3.33</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Laws</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.34</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Statements</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.34</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.34</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.1(i)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Agencies</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.20 </U>hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>&#148; means Rule 144 promulgated by the SEC pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Reports</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.8(a)</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; has the meaning set forth in the recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; has the meaning set forth in the recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Short Sales</B>&#148; include, without limitation, (i)&nbsp;all &#147;short sales&#148; as defined in Rule 200 promulgated under
Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, &#147;put equivalent positions&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) and similar arrangements (including on a total return basis), and (ii)&nbsp;sales and other transactions through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Significant Subsidiaries</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.1</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Returns</B>&#148; means returns, reports, information statements and other documentation (including any additional or supporting
material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns required as a result of examination adjustments made
by the Internal Revenue Service or other Tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; or &#147;<B>Taxes</B>&#148; means any and all federal,
state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the
Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding,
employment, social security, workers&#146; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreements</B>&#148; means this Agreement and the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Agent</B>&#148; means, with respect to the Common Stock, Computershare Trust Company, N.A., or such other financial
institution that provides transfer agent services as the Company may engage from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Taxes</B>&#148; means
all real property transfer, sales, use, value added, stamp, documentary, recording, registration, conveyance, stock transfer, intangible property transfer, personal property transfer, gross receipts, registration, duty, securities transactions or
similar fees or Taxes (together with any interest, penalty, or addition thereto) incurred in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>Purchase and Sale</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Investors, severally and not jointly, agree to purchase, up to an aggregate of $[&#149;] of Shares, with a purchase price per Share equal to the Per Share Price. Subject to and upon the terms and conditions set forth in this Agreement, at
the Closing, the Company shall issue and sell to each Investor, and each Investor, severally and not jointly, shall purchase from the Company, that number of Shares equal to (x)&nbsp;the dollar amount set forth opposite such Investor&#146;s name on
<U>Exhibit A</U> under the heading &#147;Share Purchase Price&#148; divided by (y)&nbsp;the Per Share Price, rounded down to the nearest whole share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <U>Closing</U>. Subject to the satisfaction or waiver of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;5.6</U> of this Agreement, the closing of the purchase and sale of the Shares (the &#147;<B>Closing</B>&#148; and the date on which the Closing occurs, the &#147;<B>Closing Date</B>&#148;) shall occur remotely via the
exchange of documents and signatures at such time as agreed to by the Company and the Investors but (i)&nbsp;in no event earlier than the first Business Day after the date hereof and (ii)&nbsp;in no event later than the fifth Business Day after the
date hereof. At the Closing, the Shares shall be issued and registered in the name of such Investor, or in such nominee name(s) as designated by such Investor, representing the number of Shares to be purchased by such Investor at such Closing as set
forth in <U>Exhibit A</U>, in each case against payment to the Company of the purchase price therefor (the &#147;<B>Aggregate Purchase Amount</B>&#148;) in full, by wire transfer to the Company of immediately available funds, at or prior to the
Closing, in accordance with wire instructions provided by the Company to the Investors prior to the Closing. At the Closing, the Company shall deliver to such Investor (or such Investor&#146;s designated custodian per its delivery instructions), or
in such nominee name(s) as designated by such Investor, in each case against payment to the Company of the purchase price therefor in full, by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance
with wire instructions provided by the Company to the Investors prior to the Closing. On the Closing Date, the Company will cause the Transfer Agent to issue the Shares in book-entry form, free and clear of all restrictive and other legends (except
as expressly provided in <U>Section</U><U></U><U>&nbsp;4.10</U> hereof) and the Company shall provide evidence of such issuance from the Company&#146;s Transfer Agent as of the Closing Date to each Investor. In the event that the Closing has not
occurred within one Business Day of after the expected Closing Date, unless otherwise agreed by the Company and such Investor, the Company shall promptly (but no later than one Business Day thereafter) return the previously wired Aggregate Purchase
Amount to each respective Investor by wire transfer of United States dollars in immediately available funds to the account specified by each Investor, and any book entries for the Shares shall be deemed cancelled; provided that, unless this
Agreement has been terminated pursuant to Section&nbsp;7, such return of funds shall not terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Shares at the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants to each of the Investors that the
statements contained in this <U>Section</U><U></U><U>&nbsp;3</U> are true and correct as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such
date): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Organization and Power</U>. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the 2024 SEC Reports and is qualified to do business in each jurisdiction in
which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a
Material Adverse Effect. As of the date hereof, the Company has the significant subsidiaries </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(as that term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Exchange Act) listed in Exhibit 21 to the
Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (collectively, the &#147;<B>Significant Subsidiaries</B>&#148;). Each of the Significant Subsidiaries is duly incorporated and validly existing and in good
standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on their business as now conducted and to own or lease its properties. Each of the Significant Subsidiaries is duly qualified to do
business as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required unless the failure to so qualify has not had and would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Capitalization</U>. The authorized capital stock of the Company consists of 1,000,000,000 shares of
Common Stock and 20,000,000 shares of preferred stock, par value $0.01 per share. The Company&#146;s disclosure of its issued and outstanding capital stock in the 2024 SEC Reports containing such disclosure was accurate in all material respects as
of the date indicated in such 2024 SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the
outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material respects
with applicable state and federal securities law and any rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Registration Rights</U>. Except as set forth in
the Transaction Agreements or as disclosed in the 2024 SEC Reports, the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&#146;s presently outstanding securities or
any of its securities that may hereafter be issued that have not expired or been satisfied or waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>Authorization</U>. The
Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Shares. All corporate
action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions
contemplated herein, including the issuance and sale of the Shares has been taken. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by each Investor and that this Agreement
constitutes the legal, valid and binding agreement of each Investor, this Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at
law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement will constitute a legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally
or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <U>Valid Issuance</U>. The Shares being purchased by the Investors hereunder have been
duly and validly authorized and, upon issuance pursuant to the terms hereof, against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal
securities laws) and the holder of the Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investors in <U>Section</U><U></U><U>&nbsp;4</U> hereof,
the offer and sale of the Shares to the Investors is and will be in compliance with applicable exemptions from (i)&nbsp;the registration and prospectus delivery requirements of the Securities Act and (ii)&nbsp;the registration and qualification
requirements of applicable securities laws of the states of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <U>No Conflict</U>. The execution, delivery and
performance of the Transaction Agreements by the Company, the issuance and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&nbsp;violate any provision of the Amended and
Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company, (ii)&nbsp;conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to
the Company or any Significant Subsidiary or their respective properties or assets, or (iii)<U></U>&nbsp;result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or any Significant Subsidiary is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are
subject, or by which any property or asset of the Company or any Significant Subsidiary is bound or affected,&nbsp;except, in the case of clauses (ii)&nbsp;and (iii), as would not, individually or in the aggregate, be reasonably expected to have a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <U>Consents</U>. Assuming the accuracy of the representations and warranties of the Investors, no consent,
approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the Company of the Transaction Agreements, the issuance and
sale of the Shares and the performance by the Company of its other obligations under the Transaction Agreements, except such as (a)&nbsp;have been or will be obtained or made under the Securities Act or the Exchange Act, (b)&nbsp;the filing of any
requisite notices and/or application(s) to the National Exchange for the issuance and sale of the Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (c)&nbsp;customary post-closing filings with the
SEC or pursuant to state securities laws in connection with the offer and sale of the Shares by the Company in the manner contemplated herein, which will be filed on a timely basis, and (d)&nbsp;the filing of the registration statement required to
be filed by the Registration Rights Agreement, or (e)&nbsp;such that the failure of which to obtain would not have a Material Adverse Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to
deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <U>SEC Filings; Financial Statements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has timely filed or furnished, as applicable, all forms, statements, certifications, reports and documents required to be
filed or furnished by it with the SEC under the Exchange Act or the Securities Act for the one year preceding the date hereof (the &#147;<B>SEC Reports</B>&#148;). As of the time it was filed with, or furnished to, the SEC (or, if amended or
superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the SEC Reports complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be),
and the rules and regulations promulgated thereunder, and, as of the time they were filed or furnished, none of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. None of the SEC Reports
is the subject of an ongoing SEC review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements of the Company included in the SEC Reports (collectively, the
&#147;<B>Financial Statements</B>&#148;) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a
subsequent restatement) and fairly present in all material respects the financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, all in accordance with United
States generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) (except as otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the SEC, and except
that the unaudited financial statements may not contain footnotes and are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments) applied on a consistent basis unless otherwise noted therein throughout the
periods therein specified. Except as set forth in the Financial Statements filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except (i)&nbsp;those incurred in the ordinary course of business,
consistent with past practices since the date of such financial statements or (ii)&nbsp;liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or
would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <U>Absence of Changes</U>. Except as otherwise stated or disclosed in
the 2024 SEC Reports, between June&nbsp;30, 2024 and the date of this Agreement, (a)&nbsp;the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company (except
for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or arrangement by which the Company is bound or to which any of its assets or
properties is subject has been entered into that has not been disclosed in the 2024 SEC Reports; and (c)&nbsp;there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <U>Absence of Litigation</U>. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or
inquiry pending or, to the Company&#146;s knowledge, threatened against the Company or any Significant Subsidiary which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any
orders, writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any Significant Subsidiary that have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Significant Subsidiary, nor to the knowledge of the Company, any director or officer of the
Company or any Significant Subsidiary, is, or within the last ten years has been, the subject of any action involving a claim of violation of or liability under federal or state securities laws relating to the Company or such Significant Subsidiary
or a claim of breach of fiduciary duty relating to the Company or such Significant Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Compliance with Law; Permits</U>.
None of the Company or any Significant Subsidiary is in violation of, or, to the Company&#146;s knowledge, has received any notices of violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court
or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Significant Subsidiaries have all
required licenses, permits, certificates and other authorizations (collectively, &#147;<B>Governmental Authorizations</B>&#148;) from such federal, state or local government or governmental agency, department or body that are currently necessary for
the operation of the business of the Company and its Significant Subsidiaries as currently conducted, except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material
Adverse Effect. None of the Company or any Significant Subsidiary has received any written (or, to the Company&#146;s knowledge, oral) notice regarding any revocation or material modification of any such Governmental Authorization, which,
individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Intellectual Property</U>. The Company and its Significant Subsidiaries own, or have rights to use, all material inventions, patent
applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary of confidential information, systems or procedures) and other intellectual
property as described in the 2024 SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the 2024SEC Reports) (collectively, &#147;<B>Intellectual Property</B>&#148;), except where any failure to
own, possess or acquire such Intellectual Property has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its Significant Subsidiaries has
not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, including no liens,
security interests, or other encumbrances; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. No action, suit, or other proceeding is pending, or, to the Company&#146;s knowledge, is threatened:
(A)&nbsp;challenging the Company&#146;s or its Significant Subsidiaries&#146; rights in or to any Intellectual Property; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property; or (C)&nbsp;alleging that the Company
or any of its Significant Subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in
the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Significant Subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual
Property has been licensed to the Company or any of its Significant Subsidiaries in all material respects, and to the Company&#146;s knowledge all such agreements are in full force and effect. To the Company&#146;s knowledge, there are no material
defects in any of the patents or patent applications included in the Intellectual Property. The Company and its Significant Subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <U>Employee Benefits</U>. Except as would not be reasonably likely to result in a
Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended,
and other applicable laws, rules and regulations. The Company and its Significant Subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that
are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its Significant Subsidiaries pending or, to the knowledge of the Company,
threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <U>Taxes</U>. The Company and its Significant Subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax
Returns required to have been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except for those which are being contested in good faith and except where failure to file
such Tax Returns or pay such Taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal tax returns has been made against the Company. The
charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional income tax for any years not
finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its Significant
Subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. The Company, at all times since inception, has been
and continues to be each classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its Significant Subsidiaries has been a United States real property holding corporation within the meaning of Code
Section&nbsp;897I(2) during the period specified in Code Section&nbsp;897(c)(1)(A)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <U>Environmental Laws</U>. The Company and
its Significant Subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;), (ii)&nbsp;have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct its business and (iii)&nbsp;are in
compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and
conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company or any Significant Subsidiary has received since January&nbsp;1, 2023, any
written notice or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communication (in writing or otherwise), whether from a governmental authority or other Person, that alleges that the Company or any Significant Subsidiary is not in compliance with any
Environmental Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#146;s or any Significant Subsidiary&#146;s compliance in any material respects with any Environmental Law in the
future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company: (i)&nbsp;no current or (during the time a prior property was leased or controlled by the Company) prior
property leased or controlled by the Company or any Significant Subsidiary has received since January&nbsp;1, 2023, any written notice or other communication relating to property owned or leased at any time by the Company, whether from a
governmental authority, or other Person, that alleges that such current or prior owner or the Company or any Significant Subsidiary is not in compliance with or violated any Environmental Law relating to such property and (ii)&nbsp;the Company has
no material liability under any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <U>Title</U>. Each of the Company and its Significant Subsidiaries has good and
marketable title to all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with
the use made and proposed to be made of such property by the Company or its Significant Subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its Significant Subsidiaries is held under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its Significant Subsidiaries, as the case may be. The Company does not
own any real property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <U>Insurance</U>. The Company carries or is entitled to the benefits of insurance in such amounts and
covering such risks that is customary for comparably situated companies and, in the reasonable judgement of the Company, is adequate for the conduct of its business and the value of its properties (owned or leased) and assets, and each of such
insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&nbsp;1, 2023, the Company has
not received any notice or other communication regarding any actual or possible: (i)&nbsp;cancellation or invalidation of any insurance policy or (ii)&nbsp;refusal or denial of any coverage, reservation of rights or rejection of any material claim
under any insurance policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <U>Nasdaq Stock Market</U>. The issued and outstanding shares of Common Stock are registered pursuant to
Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq Global Market under the symbol &#147;SMMT&#148;. The Company is in compliance in all material respects with all applicable listing requirements of Nasdaq applicable to
the Company. As of the date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit or terminate the listing of the
Common Stock on the Nasdaq Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <U>Sarbanes-Oxley Act</U>. The Company is, and since January&nbsp;1, 2023 has been, in compliance with all applicable requirements of the
Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20 <U>Clinical Data and Regulatory Compliance</U>. Except as would not reasonably be
expected to result in a Material Adverse Effect: (i)&nbsp;the preclinical tests and clinical trials, and other studies used to support regulatory approval (collectively, &#147;studies&#148;) being conducted by the Company that are described in, or
the results of which are referred to in, 2024 SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard
medical and scientific research procedures; (ii)&nbsp;each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its Significant
Subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the 2024 SEC Reports; (iii)&nbsp;the Company and its Significant Subsidiaries
have made all such filings and obtained all such approvals as may be required by the FDA or from any other U.S. federal, state or local government or foreign government or Drug Regulatory Agency, or Institutional Review Board, each having
jurisdiction over biopharmaceutical products (collectively, the &#147;<B>Regulatory Agencies</B>&#148;) for the conduct of its business as described in the 2024 SEC Reports; (iv)&nbsp;neither the Company nor any of its Significant Subsidiaries has
received any notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of or imposing any clinical hold on any clinical trials that are described or referred to in the 2024 SEC Reports; and (v)&nbsp;the Company
and its Significant Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <U>Compliance with Health Care Laws</U>. The Company and its Significant Subsidiaries are in compliance in all material respects with all
Health Care Laws to the extent applicable to the Company&#146;s current business and research use only products. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Section&nbsp;301 et seq.) and the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including,
without limitation, the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b));</FONT> (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) the European Union (&#147;<B>EU</B>&#148;) Clinical Trials Regulation (Regulation
(EU) No.&nbsp;536/2014); (vi) the EU Regulation regarding community procedures for authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Regulation (EC) No.&nbsp;726/2004);
(vii) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; (viii)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the
regulation of the Company or its Significant Subsidiaries, and (ix)&nbsp;the regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its
Significant Subsidiaries has received written or, to the Company&#146;s knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or
regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action threatened. The Company and its Significant Subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its Significant Subsidiaries is a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its Significant Subsidiaries nor any of their
respective employees, officers, directors, or, to the knowledge of the Company, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the
Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <U>Accounting Controls and Disclosure Controls and Procedures</U>. The Company maintains a system of internal control over financial
reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&nbsp;that the Company maintains records that in reasonable detail
accurately and fairly reflect the Company&#146;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&nbsp;that receipts and
expenditures are made only in accordance with authorizations of management and the Board and (iv)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#146;s assets that could have a
material effect on the Company&#146;s financial statements. Except as disclosed in the Company&#146;s SEC Reports filed prior to the date hereof, the Company has not identified any material weaknesses in the design or operation of the Company&#146;s
internal control over financial reporting. The Company&#146;s &#147;disclosure controls and procedures&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange
Act) are designed to provide reasonable assurance that all information (both financial and <FONT STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely
decisions regarding required disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <U>Price Stabilization of Common Stock</U>. The Company has not taken, nor will it take,
directly or indirectly, any action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24 <U>Investment Company Act</U>. The Company is not, and immediately after receipt of payment for the Common Stock will not be, an
&#147;investment company&#148; within the meaning of the U.S. Investment Company Act of 1940, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.25 <U>General Solicitation; No Integration or Aggregation</U>. Neither the Company nor any
other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of Common
Stock pursuant to this Agreement. The Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will
be (i)&nbsp;integrated with the Shares sold pursuant to this Agreement for purposes of the Securities Act or (ii)<U></U> aggregated with prior offerings by the Company for the purposes of the rules and regulations of the Nasdaq Global Market.
Assuming the accuracy of the representations and warranties of the Investors set forth in Section&nbsp;4, neither the Company nor any of its Affiliates, its Significant Subsidiaries nor any Person acting on their behalf has, directly or indirectly,
made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section&nbsp;4(a)(2) and/or Rule 506 of Regulation D promulgated
thereunder for the exemption from registration for the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.26 <U>Brokers and Finders</U>. Neither the
Company nor any other Person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.27 <U>Reliance by the Investors</U>. The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the
Company&#146;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.28 <U>N</U><U>o Disqualification Events</U>. With respect to the Shares to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act, neither the Company nor any of its (i)&nbsp;predecessors, (ii) affiliates, (iii)&nbsp;directors, (iv) executive officers, <FONT STYLE="white-space:nowrap">(v)&nbsp;non-executive</FONT> officers participating in the placement
contemplated by this Agreement, (vi)&nbsp;beneficial owners of 20% or more of its outstanding voting equity securities (calculated on the basis of voting power), (vii) promoters, or (viii)&nbsp;investment managers (including any of such investment
managers&#146; directors, executive officers or officers participating in the placement contemplated by this Agreement) or general partners or managing members of such investment managers (including any of such general partners&#146; or management
members&#146; directors, executive officers or officers participating in the placement contemplated by this Agreement) (each, an &#147;<B>Issuer Covered Person</B>&#148; and, together, &#147;<B>Issuer Covered Persons</B>&#148;) is subject to the
disqualification provisions of Rule <FONT STYLE="white-space:nowrap">506(d)(1)(i-viii)</FONT> of Regulation D under the Securities Act (a &#147;<B>Disqualification Event</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.29 <U>Other Covered Persons</U><U>. </U>The Company is not aware of any person (other than any Issuer Covered Person) that has been or will
be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.30 <U>Notice of
Disqualification Events</U>. The Company will notify the Investors in writing, prior to the Closing Date of (i)&nbsp;any Disqualification Event relating to any Issuer Covered Person and (ii)&nbsp;any event that would, with the passage of time,
reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.31
<U>No Additional Agreements</U>. To the knowledge of the Company, there are no agreements or understandings with any Investor with respect to the transactions contemplated by the Transaction Agreements other than (i)<U></U> as specified in the
Transaction Agreements and (ii)<U></U> any side letter agreements with any of the Investors, which side letters the Company has shared with any Investor that has so requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.32 <U>Anti-Bribery and Anti-Money Laundering Laws</U>. Each of the Company, its
Significant Subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not
violate: (A)<U></U> anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery
of Foreign Public Officials in International Business Transactions, signed December<U></U> 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar
purposes and scope or (B)<U></U> anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without
limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on
Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the
authority of any of the foregoing, or any orders or licenses issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.33 <U>Cybersecurity</U>. The Company and its
Significant Subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Company and its Significant Subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other
malicious code. The Company and its Significant Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability,
privacy and security of all sensitive, confidential or regulated data (&#147;<B>Confidential Data</B>&#148;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous
operation, redundancy and security of all IT Systems. &#147;<B>Personal Data</B>&#148; means the following data used in connection with the Company&#146;s and its Significant Subsidiaries&#146; businesses and in their possession or control:
(i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number, driver&#146;s license number, passport number,
credit card number or bank information; (ii)&nbsp;information that identifies or may reasonably be used to identify an individual; (iii)&nbsp;any information that would qualify as &#147;protected health information&#148; under the Health Insurance
Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (iv)&nbsp;any information that would qualify as &#147;personal data,&#148;
&#147;personal information&#148; (or similar term) under the Privacy Laws. To the Company&#146;s knowledge, there have been no breaches, outages or unauthorized uses of or accesses to the Company&#146;s IT Systems, Confidential Data, or Personal
Data that would require notification under Privacy Laws (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.34 <U>Compliance with Data Privacy Laws</U>. The Company and its Significant Subsidiaries
are, and at all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other
processing (collectively &#147;<B>Process</B>&#148; or &#147;<B>Processing</B>&#148;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (Regulation (EU) No.&nbsp;2016/679), all
other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its Significant Subsidiaries, and the regulations promulgated pursuant to such statutes and any state or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure material compliance with the Privacy Laws, the Company and its Significant Subsidiaries have in place, comply with, and
take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#147;<B>Privacy
Statements</B>&#148;). The Company and its Significant Subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times since inception provided accurate notice of
its Privacy Statements then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material
violation of any Privacy Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.35 <U>Transactions with Affiliates and Employees</U>. No relationship, direct or indirect, exists
between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the SEC Reports that is not so described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.36 <U>Reliance</U>. The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;3. The Company
acknowledges that the Investor is relying upon the accuracy and truthfulness of the foregoing representations made by the Company hereunder and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.37 <U>Shell Company Status</U>. The Company is not, and has never been, an issuer identified in Rule 144(i)(1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of Each Investor</U>. Each Investor, severally for itself and not jointly with any other Investor,
represents and warrants to the Company that the statements contained in this Section&nbsp;4 are true and correct as of the date hereof and the Closing Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization</U>. Such Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Authorization</U>. Such Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other
Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for
the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated herein has been taken. The signature of the
Investor on this Agreement is genuine and the signatory to this Agreement, if the Investor is an individual, has the legal competence and capacity to execute the same or, if the Investor is not an individual, the signatory has been duly authorized
to execute the same on behalf of the Investor. Assuming this Agreement constitutes the legal and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such Investor
in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of
creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>No Conflicts</U>. The execution, delivery and performance of the Transaction
Agreements by such Investor, the purchase of the Shares in accordance with their terms and the consummation by such Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by
such Investor (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under
(i)&nbsp;any provision of the organizational documents of such Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii)&nbsp;any
agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii),
as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of such Investor to perform its obligations under the Transaction Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Residency</U>. Such Investor&#146;s residence (if an individual) or offices in which its investment decision with respect to the
Securities was made (if an entity) are located at the address immediately below such Investor&#146;s name on <U>Exhibit A</U>, except as otherwise communicated by such Investor to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>Brokers and Finders</U>. Such Investor has not retained, utilized or been represented by any broker or finder in connection with the
transactions contemplated by this Agreement whose fees the Company would be required to pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>Investment Representations and
Warranties</U>. Each Investor hereby represents and warrants that, it (i)&nbsp;as of the date hereof is, if an entity, a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act) or an institutional
&#147;accredited investor&#148; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii)&nbsp;if an individual, is an &#147;accredited investor&#148; as that term is defined in Rule 501(a) of
Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Shares. Each Investor further represents and warrants that
(x)&nbsp;it is capable of evaluating the merits and risk of such investment, and (y)&nbsp;that it has not been organized for the purpose of acquiring the Shares and is an &#147;institutional account&#148; as defined by FINRA Rule 4512(c). Such
Investor understands and agrees that the offering and sale of the Shares has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not
involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of such Investor&#146;s representations as expressed herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <U>Intent</U>. Each Investor is purchasing the Shares solely for investment purposes,
for such Investor&#146;s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any
participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to the Investor&#146;s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with
applicable federal and state securities laws. Notwithstanding the foregoing, if such Investor is purchasing the Shares as a fiduciary or agent for one or more investor accounts, such Investor has full investment discretion with respect to each such
account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account. Each Investor has no present arrangement to sell the Shares to or through any person or
entity. Each Investor understands that the Shares must be held indefinitely unless such Shares are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be
deemed a representation or warranty by such Investor to hold the Shares for any period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <U>Investment Experience; Ability to
Protect Its Own Interests and Bear Economic Risks</U>. Each Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has knowledge and experience in finance, securities, taxation, investments and
other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal,
business and tax advice as such Investor has considered necessary to make an informed investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Investor acknowledges that such Investor
(i)&nbsp;is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies
involving a security or securities and (ii)&nbsp;has exercised independent judgment in evaluating its participation in the purchase of the Shares. Each Investor acknowledges that such Investor is aware that there are substantial risks incident to
the purchase and ownership of the Shares, including those set forth in the Company&#146;s filings with the SEC. Alone, or together with any professional advisor(s), such Investor has adequately analyzed and fully considered the risks of an
investment in the Shares and determined that the Shares are a suitable investment for the Investor. Each Investor is, at this time and in the foreseeable future, able to afford the loss of such Investor&#146;s entire investment in the Shares and
such Investor acknowledges specifically that a possibility of total loss exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <U>Independent Investment Decision</U>. Such
Investor understands that nothing in the Transaction Agreements or any other materials presented by or on behalf of the Company to such Investor in connection with the purchase of the Shares constitutes legal, tax or investment advice. Such Investor
has consulted such legal, tax and investment advisors as it, in their sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Shares Not Registered; Legends</U>. Such Investor acknowledges and agrees that the Shares are being offered in a transaction not
involving any public offering within the meaning of the Securities Act, and such Investor understands that the Shares have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the
registration requirements of the Securities Act, and that the Shares must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed of by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of
any state of the United States. Such Investor understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions
including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of such Investor&#146;s control and which the Company may not be able to satisfy, and that, if applicable,
Rule 144 may afford the basis for sales only in limited amounts. Such Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Shares. Such
Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares or made any findings or determination as to the fairness of this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Investor understands that any certificates or book entry notations evidencing the Shares may bear one or more legends in substantially
the following form and substance: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS
AMENDED (THE &#147;SECURITIES ACT&#148;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;SUCH SECURITIES HAVE BEEN REGISTERED
FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION
UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Shares may contain a legend regarding affiliate status of the Investor, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>No General Solicitation</U>. The Investor acknowledges and agrees that the Investor is purchasing the Shares directly from the
Company. Investor became aware of this offering of the Shares solely by means of direct contact from the Company as a result of a <FONT STYLE="white-space:nowrap">pre-existing,</FONT> substantive relationship with the Company and/or their respective
advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives
of such persons. The Shares were offered to Investor solely by direct contact between Investor and the Company and/or their respective representatives. Investor did not become aware of this offering of the Shares, nor were the Shares offered to
Investor, by any other means, and none of the Company and/or its representatives acted as investment advisor, broker or dealer to Investor. The Investor is not purchasing the Shares as a result of any general or public solicitation or general
advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or
any other general solicitation or general advertisement, including any of the methods described in Section&nbsp;502(c) of Regulation D under the Shares Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Access to Information</U>. In making its decision to purchase the Shares, Investor
has relied solely upon independent investigation made by Investor, upon the SEC Reports and upon the representations, warranties and covenants set forth herein. The Investor acknowledges and agrees that the Investor has received such information as
the Investor deems necessary in order to make an investment decision with respect to the Shares, including, with respect to the Company. Without limiting the generality of the foregoing, each Investor acknowledges that copies of the 2024 SEC Reports
are available on EDGAR at www.sec.gov. The Investor acknowledges and agrees that the Investor and the Investor&#146;s professional advisor(s), if any, have had the opportunity to ask such questions, receive such answers and obtain such information
from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares as the Investor and such Investor&#146;s professional advisor(s), if any, have deemed necessary to make an investment decision with
respect to the Shares and that the Investor has independently made its own analysis and decision to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise
affect such Investor&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13
<U>Certain Trading Activities</U>. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company or any other Person regarding the transaction contemplated hereby and
ending immediately prior to the date hereof. Notwithstanding the foregoing, in the case of a Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor&#146;s assets, the representation set forth above shall only apply with respect to the portion of the
assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information,
such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.14 <U>Disqualification Event</U>. To the extent the Investor is one of the covered persons identified in Rule 506(d)(1), the
Investor represents that no Disqualification Event is applicable to the Investor or any of its Rule 506(d) Related Parties (as defined below), except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3)
is applicable. The Investor hereby agrees that it shall notify the Company promptly in writing in the event a Disqualification Event becomes applicable to the Investor or any of its Rule 506(d) Related Parties, except, if applicable, for a
Disqualification Event as to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable. For purposes of this Section, &#147;<B>Rule 506(d) Related Party</B>&#148; means a person or entity that is a beneficial owner of the Investor&#146;s
securities for purposes of Rule 506(d) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Covenants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>Further Assurances</U>. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants
and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions hereof and compliance with applicable law,
including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms hereof. Each Investor acknowledges that the Company will rely on the
acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements,
representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement are no longer accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2
<U>Listing</U>. The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Market and, in accordance therewith, will use reasonable best efforts to comply in all material
respects with the Company&#146;s reporting, filing and other obligations under the rules and regulations of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Disclosure of
Transactions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall, by 5:30 p.m., New York City time, on the first (1st) Business Day immediately following the
date hereof, file with the SEC one or more Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including all exhibits thereto, the &#147;<B>Disclosure Documents</B>&#148; and such date, the &#147;<B>Disclosure Date</B>&#148;)
disclosing (i)&nbsp;all material terms of the transactions contemplated hereby and by the other Transaction Agreements and attaching this Agreement and the other Transaction Agreements as exhibits to such Disclosure Documents, and (ii)&nbsp;all
material <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company disclosed to the Investors. Following the Disclosure Date, no Investor shall be in possession of any material
<FONT STYLE="white-space:nowrap">non-public</FONT> information received from the Company, its subsidiaries or any of their respective officers, directors, employees or agents. Notwithstanding anything in this Agreement to the contrary, the Company
shall not publicly disclose the name of any Investor or any of its affiliates or advisers, or include the name of any Investor or any of its affiliates or advisers in any press release or filing with the SEC (other than any registration statement
contemplated by the Registration Rights Agreement) or any regulatory agency, without the prior written consent of such Investor, except (i)&nbsp;as required by the federal securities law in connection with (A)&nbsp;any registration statement
contemplated by the Registration Rights Agreement, (B)&nbsp;the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities or (C)&nbsp;a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> disclosing the transactions contemplated hereby, or (ii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq
Global Market. For the avoidance of doubt, the Investors acknowledge that the Company will file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> which will name the Investors, specify the number of shares purchased and the price
per share, and will include copies of the Transaction Agreements as an exhibit to such filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Disclosure Documents shall include all material
<FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company disclosed to the Investors. Following the Disclosure Date, no Investor shall be in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT>
information received from the Company, its subsidiaries or any of their respective officers, directors, employees or agents (including the Placement Agents). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Integration</U>. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner that would require
the registration under the Securities Act of the sale of the Shares to the Investors, or that will be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any National Exchange such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Removal of Legends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant to
any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company
shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as
reasonably practicable following any such request therefor from such Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection
therewith. The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation
reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i)&nbsp;have been registered under the Securities Act pursuant to an effective registration statement or
(ii)&nbsp;have been sold pursuant to Rule 144, the Company shall, in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;5.5(b)</U> and as soon as reasonably practicable following any request therefor from an Investor accompanied by
such customary and reasonably acceptable documentation referred to above, (A)&nbsp;deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B)&nbsp;cause its
counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of the legend in
accordance with the provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Withholding Taxes</U>. Each Investor agrees to furnish the Company with any
information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <U>Fees and Taxes</U>. The Company shall be solely responsible for the payment of any financial advisory fees, or broker&#146;s
commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <U>No
Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company&#146;s obligations to the Investors under the Transaction
Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9 <U>Reporting Status</U>. The Company shall timely file all reports required to be filed with the SEC pursuant to the
Exchange Act, and the Company shall not terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would otherwise permit such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <U>Indemnification.</U><U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees,
members, managers, employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs
of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse
any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from such Person&#146;s fraud or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person entitled to indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with respect to which it
seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right
to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses,
(b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&nbsp;in the reasonable judgment of any such person, based upon written advice of its counsel, a
conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the
indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not
relieve the indemnifying party of its obligations hereunder, except to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall
not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the
indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i)&nbsp;imposes no liability or obligation on,
(ii)&nbsp;includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in
favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which
consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11
<U>Subsequent Equity Sales</U>. From the date hereof until the earlier of (a)&nbsp;sixty (60) days after the Closing Date and (b)&nbsp;the Business Day immediately following the effective date of the registration statement filed pursuant to the
Registration Rights Agreement, the Company shall not (A)&nbsp;effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Stock or (B)&nbsp;file with the SEC a
registration statement under the Securities Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement. Notwithstanding the foregoing, the provisions of this
Section&nbsp;5.11 shall not apply to the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register the offer and sale of securities on an equity incentive plan or employee stock
purchase plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Conditions to the Obligation of the Investors</U>. The several obligations of each Investor to consummate the transactions to be
consummated at the Closing, and to purchase and pay for the Shares being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in
all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date hereof and as of the Closing Date, as though made on and as of
such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those
representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance</U>. The Company shall have performed in all material respects the obligations and conditions herein required to be
performed or observed by the Company on or prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>No Injunction</U>. The purchase of and payment for the Shares by each Investor shall
not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Consents</U>. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the
consummation of the purchase and sale of the Shares, all of which shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Transfer Agent</U>. The
Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Shares at the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)
<U>Adverse Changes</U>. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Compliance Certificate</U>. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a
certificate certifying that the conditions specified in <U>Sections 6.1(a) (Representations and Warranties)</U>, <U>6.1(b) (Performance)</U>, <U>6.1(c) (No Injunction)</U>, <U>6.1(d) (Consents)</U>, <U>6.1(e) (Transfer </U><U>Agent)</U>, <U>6.1(f)
(Adverse Changes)</U>, <U>6.1(j) (Listing Requirements)</U> and <U>6.1(l)</U> of this Agreement have been fulfilled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)
<U>Secretary&#146;s Certificate</U>. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i)&nbsp;the Amended and Restated Certificate of Incorporation; (ii)&nbsp;the Amended and Restated
Bylaws; and (iii)&nbsp;resolutions of the Company&#146;s Board of Directors (or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Rights Agreement</U>. The Company shall have executed and delivered the Registration Rights Agreement in the
form attached hereto as <U>Exhibit B</U> (the &#147;<B>Registration Rights Agreement</B>&#148;) to the Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Listing
Requirements</U>. No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National
Exchange and shall not have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange have been threatened, as of the Closing Date, in writing by the SEC
or the National Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>No Injunction</U>. No judgment, writ, order, injunction, award or decree of or by any court, or judge,
justice or magistrate, including any bankruptcy court or judge, or any order of or by any Governmental Entity, shall have been issued, and no action or proceeding shall have been instituted by any Governmental Entity, enjoining or preventing the
consummation of the transactions contemplated hereby or in the other Transaction Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conditions to the Obligation of the Company</U>. The obligation of the Company to
consummate the transactions to be consummated at the Closing, and to issue and sell to each Investor the Common Stock to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the
following conditions precedent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of each Investor in
Section&nbsp;4 hereto shall be true and correct on and as of the Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall constitute a reaffirmation by the Investor of each of
the representations, warranties, covenants and agreements of the Investor contained in this Agreement as of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
<U>Performance</U>. Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Injunction</U>. The purchase of and payment for the Shares by each Investor shall not be prohibited or enjoined by any law or
governmental or court order or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Registration Rights Agreement</U>. Each Investor shall have executed and delivered the
Registration Rights Agreement to the Company in the form attached as <U>Exhibit</U><U></U><U>&nbsp;B</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Payment</U>. The
Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Shares being purchased by each Investor at the Closing as set forth in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1
<U>Termination</U>. The obligations of the Company, on the one hand, and the Investor, on the other hand, to effect the Closing shall terminate as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the mutual written consent of the Company and the Investor prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) By the Company if any of the conditions set forth in Section&nbsp;6.2 shall have become incapable of fulfillment, and shall not have
been waived by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) By the Investor if any of the conditions set forth in Section&nbsp;6.1 shall have become incapable of
fulfillment, and shall not have been waived by the Investor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) By either the Company or the Investor if the Closing has not
occurred on or prior to the fifth Business Day following the date of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">provided, however, that, except in the case of
clauses (ii)&nbsp;and (iii) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such
breach has resulted in the circumstances giving rise to such party&#146;s seeking to terminate its obligation to effect the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Notice</U>. In the event of termination by the Company or the Investor of its
obligations to effect the Closing pursuant to Section&nbsp;7.1, written notice thereof shall be given to the other party. Nothing in this Section&nbsp;7 shall be deemed to release any party from any liability for any breach by such party of the
other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <U>Public Statements or Releases</U>. Except as set forth in Section&nbsp;5.3, neither the Company nor any Investor shall make any public
announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the foregoing, and subject
to compliance with Section&nbsp;5.3, nothing in this Section&nbsp;8.1 shall prevent any party from making any public announcement it considers necessary in order to satisfy its obligations under the law, including applicable securities laws, or
under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investor reasonable time to comment on such release or announcement in advance of such issuance. The Company shall not include the
name of the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC) without the prior written consent of the Investor, except as otherwise required by law or the applicable
rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Investor, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in
advance of such issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Interpretation</U>. The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words
of similar import when used in this Agreement will refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and subsection references are to this Agreement unless otherwise specified. The headings in this
Agreement are included for convenience of reference only and will not limit or otherwise affect the meaning or interpretation of this Agreement. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this
Agreement, they will be deemed to be followed by the words &#147;without limitation.&#148; The phrases &#147;the date of this Agreement,&#148; &#147;the date hereof&#148; and terms of similar import, unless the context otherwise requires, will be
deemed to refer to the date set forth in the first paragraph of this Agreement. The meanings given to terms defined herein will be equally applicable to both the singular and plural forms of such terms. All matters to be agreed to by any party
hereto must be agreed to in writing by such party unless otherwise indicated herein. References to agreements, policies, standards, guidelines or instruments, or to statutes or regulations, are to such agreements, policies, standards, guidelines or
instruments, or statutes or regulations, as amended or supplemented from time to time (or to successors thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Notices</U>. Any
notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by
electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#146;s next Business Day, (c)&nbsp;three (3) days after having been sent by certified or registered mail,
return-receipt requested and postage prepaid, or (d)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Company, addressed as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Summit Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">601 Brickell Key Drive, Suite 1000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Miami, Florida 33131 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Manmeet Soni and Susan Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: manmeet.soni@smmttx.com and </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">susan.kim@summitplc.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Baker&nbsp;&amp; Hostetler LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">45 Rockefeller Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10111 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Adam W. Finerman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: afinerman@bakerlaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If to any Investor, at its address set forth on <U>Exhibit A</U> or to such <FONT STYLE="white-space:nowrap">e-mail</FONT> address, or
address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;8.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person may
change the address to which notices and communications to it are to be addressed by notification as provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <U>Consent
to Electronic Notice</U>. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the &#147;DGCL&#148;), as amended or superseded from time to time, by electronic mail pursuant to
Section&nbsp;232 of the DGCL (or any successor thereto) at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth below such Investor&#146;s name on the signature page or Exhibit A, as updated from time to time by notice to the
Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected <FONT STYLE="white-space:nowrap">e-mail</FONT>
address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its <FONT STYLE="white-space:nowrap">e-mail</FONT>
address, and that failure to do so shall not affect the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Severability</U>. If any part or provision of this Agreement is
held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business
purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws
or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of the Investors hereby irrevocably and unconditionally: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated
hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the City of New York in the State of New York; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to
the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified
mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section</U><U></U><U>&nbsp;8.3</U> or at such other address of which the other party shall have been notified
pursuant thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by
law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i)&nbsp;are not available despite the intentions of the parties
hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of
any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal
process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <U>Waiver</U>. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more
instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <U>Expenses</U>. Except as expressly set forth in the Transaction Agreements to the
contrary, each party shall pay its own <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party,
incurred in connection with the proposed investment in the Shares and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required
for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction letter delivered by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Shares to the
Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <U>Assignment</U>. None of the parties may assign its rights or obligations under this Agreement or designate another
person (i)&nbsp;to perform all or part of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x)&nbsp;the Company, in the case of
an Investor, and (y)&nbsp;the Investors, in the case of the Company, provided that an Investor may, without the prior consent of the Company, assign its rights to purchase the Shares hereunder to any of its affiliates or to any other investment
funds or accounts managed or advised by the investment manager who acts on behalf of such Investor (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;4</U> hereof). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be
bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve
any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <U>Confidential
Information</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each Investor covenants that until such time as the transactions contemplated by this Agreement and any material <FONT
STYLE="white-space:nowrap">non-public</FONT> information provided to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction), other than to such Investor&#146;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or
required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The
Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide such information
as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor confidential, except (i)&nbsp;as required by the federal securities laws, rules or regulations
and (ii)&nbsp;to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Investor acknowledges that the Company may file a copy
of this Agreement and the Registration Rights Agreement with the SEC as exhibit to a periodic report or a registration statement of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <U>Third Parties</U>. Nothing in this Agreement, express or implied, is intended to
confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without
limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any
standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <U>Independent Nature
of Investors</U><U>&#146;</U><U> Obligations and Right</U><U>.</U> The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the
performance obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not
so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such
obligations or the transactions contemplated by this Agreement. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel
and advisors. Each Investor also acknowledges that Baker&nbsp;&amp; Hostetler LLP has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with the same terms and Transaction
Agreements for the convenience of the Company and not because it was required or requested to do so by any Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.10
<U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.11 <U>Counterparts</U>. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of
2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a)
signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.12 <U>Entire Agreement; Amendments</U>. This Agreement and the other Transaction Agreements (including all schedules and
exhibits hereto and thereto), together with any side letter agreements with any of the Investors, which side letters the Company has shared with any Investor that has so requested, constitute the entire agreement between the parties hereto
respecting the subject matter hereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof, whether written or oral. No amendment, modification, alteration, or change
in any of the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company and the Investors of at least a majority in interest of the Shares then held by the Investors.
Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to
all Investors in the same fashion. The Company, on the one hand, and each Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company,
respectively, with any term or provision hereof or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.13 <U>Survival</U>. The covenants, representations and warranties made by each party
hereto contained in this Agreement shall survive the Closing and the delivery of the Shares in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.14 <U>Mutual Drafting</U><U>.</U> This Agreement is the joint product of each Investor and the Company and each provision
hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.15 <U>Arm</U><U>&#146;</U><U>s Length Negotiations</U>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and
conditions of the Shares were determined as a result of <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.18
<U>Further Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SUMMIT THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Manmeet Soni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[&#149;]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Investor Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$22.70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[&#149;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>[&#149;]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>$[&#149;]</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF REGISTRATION RIGHTS AGREEMENT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d799002dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS REGISTRATION RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;), dated as of September&nbsp;11, 2024, is entered into by and
among Summit Therapeutics Inc.,<B> </B>a Delaware corporation (the &#147;<B>Company</B>&#148;), and the several investors signatory hereto (individually as an &#147;<B>Investor</B>&#148; and collectively together with their respective permitted
assigns, the &#147;<B>Investors</B>&#148;).&nbsp;Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date
hereof (as amended, restated, supplemented or otherwise modified from time to time, the &#147;<B>Purchase Agreement</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHEREAS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Upon the
terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investors, and the Investors have agreed to purchase, severally and not jointly, an aggregate of&nbsp;up to $[&#149;] of shares (the
&#147;<B>Shares</B>&#148;) of the Company&#146;s common stock, par value $0.01 per share (the &#147;<B>Common Stock</B>&#148;), pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. To induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S.
Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#147;<B>Securities Act</B>&#148;), and applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1. DEFINITIONS.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Person</B>&#148; means any individual or entity including but not limited to any corporation, limited liability company,
association, partnership, organization, business, individual, governmental or political subdivision thereof or a governmental agency. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
&#147;<B>Register</B>,&#148; &#147;<B>Registered</B>,&#148; and &#147;<B>Registration</B>&#148; refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and
providing for offering securities on a continuous basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Registrable Securities</B>&#148; means the Shares and any Common Stock issued or issuable with respect to the Shares as a result
of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities upon the date on which the Investors shall have resold all the Registrable Securities
covered by the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Registration Expenses</B>&#148; means all registration and filing fee expenses
incurred by the Company in effecting any registration pursuant to this Agreement, including (i)&nbsp;all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings required to be made
with the SEC, FINRA or any other regulatory authority, (ii)&nbsp;all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any securities or &#147;Blue Sky&#148; laws, (iii)&nbsp;all printing,
duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv)&nbsp;all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of
any special audit and cold comfort letters required by or incident to such performance). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Registration Statement</B>&#148; means any registration statement of the
Company filed with, or to be filed with, the SEC under the Securities Act, that Registers Registrable Securities, including the related prospectus, amendments and supplements to such registration statement, including
<FONT STYLE="white-space:nowrap">pre-</FONT> and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws. &#147;Registration
Statement&#148; shall also include a New Registration Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a prospectus
subsequently filed with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Selling Expenses</B>&#148; means all underwriting discounts and selling commissions
applicable to the sale of Registrable Securities and all similar fees and commissions relating to the Investors&#146; disposition of the Registrable Securities. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGISTRATION. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Mandatory Registration</U>.&nbsp;The Company shall, as promptly as reasonably practicable and in any event no later than
November&nbsp;11, 2024 (the &#147;<B>Filing Deadline</B>&#148;), prepare and file with the SEC an initial Registration Statement (the &#147;<B>Initial Registration Statement</B>&#148;) covering the resale of all Registrable Securities. Before filing
the Registration Statement, the Company shall furnish to the Investors a copy of the Registration Statement. The Investors and their counsel shall have at least three (3)&nbsp;Business Days prior to the anticipated filing date of a Registration
Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus (including any documents incorporated by reference therein), prior to its filing with the SEC.
The Company shall (a)&nbsp;use its reasonable best efforts to address in each such document prior to being so filed with the SEC such comments as the Investor or its counsel reasonably proposed by the Investor, and (b)&nbsp;not file any Registration
Statement or related prospectus or any amendment or supplement thereto containing information regarding the Investor to which Investor reasonably objects, unless such information is required to comply with any applicable law or regulation. The
Investors shall furnish all information reasonably requested by the Company and as shall be reasonably required in connection with any registration referred to in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Effectiveness.</U>&nbsp;The Company shall use its reasonable best efforts to have the Initial Registration Statement and any amendment
declared effective by the SEC at the earliest possible date but no later than the earlier of the seventy-fifth (75th) calendar day following the initial filing date of the Initial Registration Statement if the SEC notifies the Company that it will
&#147;review&#148; the Initial Registration Statement and (b)&nbsp;the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Initial Registration Statement will not be
&#147;reviewed&#148; or will not be subject to further review (the &#147;Effectiveness Deadline&#148;). The Company shall notify the Investor by <FONT STYLE="white-space:nowrap">e-mail</FONT> as promptly as practicable, and in any event, within
twenty-four (24)&nbsp;hours, after the Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any related Prospectus to be used in connection with the sale or other disposition of the securities
covered thereby. The Company shall use reasonable best efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investors of all of the
Registrable Securities covered thereby at all times until the earliest to occur of the following events: (i)&nbsp;the date on which the Investors shall have resold all the Registrable Securities covered thereby;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (ii)&nbsp;the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any
other rule of similar effect (the &#147;Registration Period&#148;). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Sufficient Number of Shares Registered</U>.&nbsp;In the event the number of shares available under the Initial Registration Statement at
any time is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus
supplements thereunder, a &#147;<B>New Registration Statement</B>&#148;), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than ten (10)&nbsp;Business Days after the necessity therefor
arises (the &#147;<B>New Registration Filing Deadline</B>&#148;).&nbsp;The Company shall use its reasonable best efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing
thereof but no later than the earlier of the seventy-fifth (75th) calendar day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will &#147;review&#148; the New Registration Statement and
(b)&nbsp;the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review (the
earlier of such dates, the &#147;<B>New Registration</B><U> </U><B>Effectiveness Deadline</B>&#148;). The provisions of Section&nbsp;2(a) and (b)&nbsp;shall apply to the New Registration Statement, except as modified hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Liquidated Damages</U>.&nbsp;If (i)&nbsp;the Initial Registration Statement has not been filed by the Filing Deadline, (ii)&nbsp;the
Initial Registration Statement has not been declared effective by the Effectiveness Deadline, (iii)&nbsp;the New Registration Statement has not been filed by the New Registration Filing Deadline, (iv)&nbsp;the New Registration Statement has not been
declared effective by the New Registration Effectiveness Deadline or (v)&nbsp;after any Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement for any reason (including without
limitation by reason of a stop order, or the Company&#146;s failure to update such Registration Statement), but excluding any Allowed Delay (as defined below) or, if the Registration Statement is on Form <FONT STYLE="white-space:nowrap">S-1,</FONT>
for a period of twenty (20)&nbsp;days following the date on which the Company files a post-effective amendment to incorporate the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (a &#147;<B>Maintenance
Failure</B>&#148;), then the Company will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages and not as a penalty, in an amount equal to 0.5% of the aggregate amount paid pursuant to the Purchase
Agreement by such Investor for such Registrable Securities then held by such Investor for each <FONT STYLE="white-space:nowrap">30-day</FONT> period or pro rata for any portion thereof during which the failure continues (the &#147;<B>Blackout
Period</B>&#148;). Such payments shall constitute the Investors&#146; exclusive monetary remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. The amounts payable as liquidated damages pursuant to this
paragraph shall be paid in cash no later than five (5)&nbsp;Business Days after each such <FONT STYLE="white-space:nowrap">30-day</FONT> period following the commencement of the Blackout Period until the termination of the Blackout Period (the
&#147;<B>Blackout Period Payment Date</B>&#148;). Interest shall accrue at the rate of 0.5% per month on any such liquidated damages payments that shall not be paid by the Blackout Period Payment Date until such amount is paid in full.
Notwithstanding the above, in no event shall the aggregate amount of liquidated damages (or interest thereon) paid under this Agreement to any Investor exceed, in the aggregate, 2.5% of the aggregate purchase price of the Shares purchased by such
Investor under the Purchase Agreement. Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;2(d)</U> to the contrary, during any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the
Registrable Securities because any Investor fails to furnish information required to be provided pursuant to <U>Section</U><U></U><U>&nbsp;2(a)</U> or <U>Section</U><U></U><U>&nbsp;4(a)</U> within three (3)&nbsp;Business Days of the Company&#146;s
request, any liquidated damages that would otherwise accrue as to such Investor only shall be tolled until such information is delivered to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Allowable Delays.</U>&nbsp;On no more than two occasions and for not more than sixty
(60)&nbsp;consecutive days or for a total of not more than one hundred twenty (120)&nbsp;days in any twelve (12)&nbsp;month period, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or
suspend the use of any prospectus included in any Registration Statement, in the event that the Company determines in good faith that such delay or suspension is necessary to (A)&nbsp;delay the disclosure of material
<FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B)&nbsp;amend or supplement the
affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading (an &#147;<B>Allowed Delay</B>&#148;); provided, that the Company shall promptly (a)&nbsp;notify each Investor in writing
of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material <FONT STYLE="white-space:nowrap">non-public</FONT> information giving rise to an Allowed Delay,
(b)&nbsp;advise the Investors in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c)&nbsp;use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Rule</U><U></U><U>&nbsp;415; Cutback</U>. If at any time the SEC takes the position that the offering of some or all of the Registrable
Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&nbsp;415 under the Securities Act (provided, however, the Company shall be obligated to use reasonable best efforts to
advocate with the SEC for the registration of all of the Registrable Securities) or requires any Investor to be named as an &#147;underwriter,&#148; the Company shall (i)&nbsp;promptly notify each holder of Registrable Securities thereof and
(ii)&nbsp;make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#147;by or on behalf of the issuer&#148; as defined in Rule&nbsp;415
and that none of the Investors is an &#147;underwriter.&#148; The Investors shall have the right to have its legal counsel, at such Investor&#146;s expense, to review and oversee any registration or matters pursuant to this
<U>Section</U><U></U><U>&nbsp;2(f)</U>, including participation in any meetings or discussions with the SEC regarding the SEC&#146;s position and to comment on any written submission made to the SEC with respect thereto. No such written submission
with respect to this matter shall be made to the SEC to which any Investor&#146;s counsel reasonably objects. In the event that, despite the Company&#146;s reasonable best efforts and compliance with the terms of this
<U>Section</U><U></U><U>&nbsp;2(f)</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from such Registration Statement such portion of the Registrable Securities (the &#147;<B>Cut Back Shares</B>&#148;) and/or
(ii)&nbsp;agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&#146;s compliance with the requirements of Rule&nbsp;415 (collectively, the &#147;<B>SEC
Restrictions</B>&#148;); provided, however, that the Company shall not name any Investor as an &#147;underwriter&#148; in such Registration Statement without the prior written consent of such Investor (provided that, in the event an Investor
withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be
named as an &#147;underwriter&#148; in such Registration Statement or such Investor otherwise consents in writing to being so named). Any <FONT STYLE="white-space:nowrap">cut-back</FONT> imposed on the Investors pursuant to this
<U>Section</U><U></U><U>&nbsp;2(f)</U> shall be allocated among the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities of such Investor as such Investor shall designate, unless the SEC Restrictions
otherwise require or provide or the Investors otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC
Restrictions applicable to such Cut Back Shares (such date, the &#147;<B>Restriction Termination Date</B>&#148;). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U> (including the Company&#146;s obligations with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the filing of a Registration Statement and its obligations to use reasonable efforts to have such Registration Statement declared effective within the time periods set forth herein and
the liquidated damages provisions relating thereto) shall again be applicable to such Cut Back Shares; <U>provided</U>, <U>however</U>, that&nbsp;the date by which the Company is required to file the Registration Statement with respect to such Cut
Back Shares shall be the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day following the Restriction Termination Date and the date by which the Company is required to have the Registration Statement effective with respect to such
Cut Back Shares shall be the fifty-fifth (55<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day immediately after the Restriction Termination Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3. RELATED COMPANY OBLIGATIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to
<U>Section</U><U></U><U>&nbsp;2</U>, including on the Initial Registration Statement or on any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with
the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Notifications</U>. The Company will promptly notify the Investors promptly of the time when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been
filed with the SEC and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any
New Registration Statement or any prospectus or for additional information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendments.</U> The Company will prepare and file with
the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement, any New Registration Statement or any related prospectus, as applicable, that, (a)&nbsp;as may be necessary to keep such Registration Statement
effective for the Effectiveness Period and to comply with the provisions of the Securities Act and the Exchange Act with respect to the distribution of all of the Registrable Securities covered thereby, or (b)&nbsp;in the reasonable opinion of the
Investors and the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Investor Review</U>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement
or any prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A)&nbsp;the Investors and their counsel shall have been advised and afforded the
opportunity to review and comment thereon at least one (1)&nbsp;Business Day prior to filing with the SEC and (B)&nbsp;the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Copies Available</U>. The Company will furnish to any Investor whose Registrable Securities are included in any Registration
Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New Registration Statement and all amendments to
the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by
reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any
portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by Investor
that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor&#146;s request and in such quantities as such Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that
the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Notification of Stop Orders; Material Changes</U>. The Company shall use best efforts
to (i)&nbsp;prevent the issuance of any stop order or other suspension of effectiveness and, (ii)&nbsp;if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in
no event later than 24 hours) and shall confirm such advice in writing, in each case: (i)&nbsp;of the Company&#146;s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to
the Registration Statement or any prospectus or for any additional information; (ii)&nbsp;of the Company&#146;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the
effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company&#146;s receipt of any notification of the suspension of
qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii)&nbsp;of the Company becoming aware of the happening of any event, which
makes any statement of a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus in order to
state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, or of
the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth
in clause (i)&nbsp;to (iii) of the immediately preceding sentence (each, a &#147;<B>Suspension Event</B>&#148;), but rather, shall only be required to disclose that the event has occurred. If at any time the SEC, or any other federal or state
governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use its reasonable best efforts to obtain
the withdrawal of such order at the earliest practicable time. The Company shall furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the
Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii)&nbsp;of the
first sentence of this <U>Section</U><U></U><U>&nbsp;3(e)</U>, the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under
Registration Statements may resume; <U>provided</U>, <U>however</U>, that if the Company has a bona fide business purpose for not making such information public, the Company may suspend the use of all Registration Statements for up to sixty
(60)&nbsp;consecutive calendar days; <U>provided</U>, <U>further</U>, that the Company may not suspend the use of all Registration Statements more than twice, or for more than ninety (90)&nbsp;total calendar days, in each case during any
twelve-month period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Confirmation of Effectiveness</U>. If reasonably requested by an Investor at any time in respect of any
Registration Statement, the Company shall deliver to such Investor a written confirmation from Company&#146;s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without
limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Listing</U>. The Company shall use best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on
the Nasdaq Global Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Compliance</U>. The Company shall otherwise use best efforts to comply with all
applicable rules and regulations of the SEC under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), including, without limitation, Rule 172 under the Securities Act, file any final
prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Effectiveness Period, the Company does not satisfy the
conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the
registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least
twelve (12)&nbsp;months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose
of this subsection 3(h), &#147;Availability Date&#148; means the forty-fifth (45<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day following the end of the fourth fiscal quarter that includes the effective date of such Registration
Statement, except that, if such fourth fiscal quarter is the last quarter of the Company&#146;s fiscal year, &#147;Availability Date&#148; means the ninetieth (90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after the end of such
fourth fiscal quarter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U><FONT STYLE="white-space:nowrap">Blue-Sky</FONT></U>. The Company shall use best efforts to register or
qualify or cooperate with the Investor and their counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by
the Investor; <U>provided</U>, <U>however</U>, that the Company shall not be required in connection therewith or as a condition thereto to (i)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to qualify but
for this <U>Section</U><U></U><U>&nbsp;3(i)</U>, (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this <U>Section</U><U></U><U>&nbsp;3(i)</U>, or (iii)&nbsp;file a general consent to
service of process in any such jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Rule 144</U>. With a view to making available to the Investors the benefits of
Rule&nbsp;144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to: (i)&nbsp;make and
keep adequate current public information available, as those terms are understood and defined in Rule&nbsp;144, until the earlier of (A)&nbsp;six (6)&nbsp;months after such date as all of the Registrable Securities may be sold without restriction by
the holders thereof pursuant to Rule&nbsp;144 or any other rule of similar effect or (B)&nbsp;such date as there are no longer Registrable Securities; (ii)&nbsp;file with the SEC in a timely manner all reports and other documents required of the
Company under the Exchange Act; (iii)&nbsp;furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A)&nbsp;a written statement by the Company that it has complied with the reporting
requirements of the Exchange Act, (B)&nbsp;a copy of or electronic access to the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT>
and (C)&nbsp;such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration and (iv)&nbsp;provide any legal
opinions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Cooperation.</U>&nbsp;The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely
preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common
Stock and registered in such names as the holders of the Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule 144 to effect sales of Registrable Securities ; for the avoidance of doubt, the
Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#146;s Direct Registration System. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Removal of Restrictive Legends</U>.&nbsp;The Company shall use reasonable best
efforts to cause the Company&#146;s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable following such request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>4. OBLIGATIONS OF THE INVESTORS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Investor Information</U>. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as <U>Exhibit A</U>
in connection with the registration of the Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Suspension of Sales</U>. Each Investor, severally and not
jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of Suspension Event as set forth in <U>Section</U><U></U><U>&nbsp;3(e)</U>, the Investor will immediately discontinue disposition of
Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor&#146;s receipt of a notice from the Company confirming the resolution of such Suspension Event and that such dispositions may again
be made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Investor Cooperation</U>. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the
Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in
writing of its election to exclude all of its Registrable Securities from such Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>5. EXPENSES OF REGISTRATION.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All
Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number of Registrable Securities so registered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6. INDEMNIFICATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investors, each Person, if any, who controls the Investors, the members, the directors, officers, partners, employees, members,
managers, agents, representatives and advisors of the Investors and each Person, if any, who controls the Investors within the meaning of the Securities Act or the Exchange Act (each, an &#147;<B>Indemnified Person</B>&#148;), against any losses,
obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs and costs of preparation, reasonable and documented attorneys&#146; fees, amounts paid in settlement
(with the prior consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed) or reasonable and documented expenses, (collectively, &#147;<U>Claims</U>&#148;)) reasonably incurred in investigating, preparing or
defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or
not an indemnified party is or may be a party thereto (&#147;<B>Indemnified Damages</B>&#148;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out
of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or
supplement thereof, or (ii)&nbsp;any violation or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other &#147;blue sky&#148; laws of any jurisdiction in which
Registrable Securities are offered or any rule or regulation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the
matters in the foregoing clauses (i)&nbsp;and (ii) being, collectively, &#147;<B>Violations</B>&#148;).&nbsp;The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim.&nbsp;Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this <U>Section</U><U></U><U>&nbsp;6(a)</U>: (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in
reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement or prospectus and was reviewed and approved in writing by such
Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each case if the foregoing was timely made
available by the Company; (B)&nbsp;with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to
the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was
promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a violation; (C)&nbsp;shall not be available to the extent such Claim is based on a failure of the Investors to deliver, or cause
to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities; and (D)&nbsp;shall not apply
to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed.&nbsp;Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to <U>Section</U><U></U><U>&nbsp;8</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, the Investors, severally and not
jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed<B> </B>the Initial Registration Statement or signs any New Registration Statement, each Person, if any, who controls the
Company within the meaning of the Securities Act or the Exchange Act (collectively and together with an Indemnified Person, an &#147;<B>Indemnified Party</B>&#148;), against any losses, claims, damages, liabilities and expense (including reasonable
attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information about the Investors furnished in writing by the Investor to the Company
and reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus or any such amendment thereof or
supplement thereto. In no event shall the liability of Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by Investor in connection with any claim relating to this <U>Section</U><U></U><U>&nbsp;6</U> and
the amount of any damages Investor has otherwise been required to pay by reason of such untrue statement or omission) received by Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such
indemnification obligation. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by any Investor pursuant to
<U>Section</U><U></U><U>&nbsp;8</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an Indemnified Person or Indemnified Party under this
<U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is
to be made against any indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory
to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses
subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; <U>provided</U>, <U>however</U>, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and
Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained
by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or
Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim
by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim.&nbsp;The indemnifying party shall keep the Indemnified
Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto.&nbsp;No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its
written consent, <U>provided</U>, <U>however</U>, that the indemnifying party shall not unreasonably withhold, delay or condition its consent.&nbsp;No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person,
consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving of a complete,
explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii)&nbsp;does not include
any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person..&nbsp;Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to
all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.&nbsp;The failure to deliver written notice to the indemnifying party
within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this <U>Section</U><U></U><U>&nbsp;6</U>, except to the extent that the
indemnifying party is prejudiced in its ability to defend such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The indemnification required by this
<U>Section</U><U></U><U>&nbsp;6</U> shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.&nbsp;Any Person receiving a payment
pursuant to this <U>Section</U><U></U><U>&nbsp;6</U> which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The indemnity agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Indemnified Party or
Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be subject to pursuant to the law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7. CONTRIBUTION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the
extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under
<U>Section</U><U></U><U>&nbsp;6</U> to the fullest extent permitted by law; <U>provided</U>, <U>however</U>, that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of
<U>Section</U><U></U><U>&nbsp;11(f)</U> of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was not guilty of fraudulent misrepresentation; and (ii)&nbsp;contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses
paid by such holder in connection with any claim relating to this <U>Section</U><U></U><U>&nbsp;7</U> and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or
alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.
ASSIGNMENT OF REGISTRATION RIGHTS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall not assign this Agreement or any rights or obligations hereunder (whether by
operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding; <U>provided</U>, <U>however</U>, that in any transaction, whether by merger, reorganization,
restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such
Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#147;Company&#148; shall be deemed to refer to such Person and the term &#147;Registrable Securities&#148; shall be deemed to
include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding
a majority of the Registrable Securities then outstanding shall not be required for such transaction.&nbsp;No Investor may assign its rights under this Agreement, other than to an affiliate of such Investor, without the prior written consent of the
Company. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>9. AMENDMENTS AND WAIVERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a
written instrument executed by (i)&nbsp;the Company and (ii)&nbsp;the holders of a majority of the then outstanding Registrable Securities (voting together as a single class), <U>provided</U> that any party may give a waiver as to itself and
provided further that any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require
the prior written consent of such adversely affected Investor or each Investor, as applicable. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of
one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding all of the Registrable Securities to which such waiver or consent relates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>10. MISCELLANEOUS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Notices</U>. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when
delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#146;s next business day, (c)&nbsp;three (3) days after having been sent by certified or
registered mail, return-receipt requested and postage prepaid, or (d)&nbsp;one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of
receipt: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. If to the Company, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Summit Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">601
Brickell Key Drive, Suite 1000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Miami, FL 33131 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: Manmeet Soni and Susan Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: manmeet.soni@smmttx.com; susan.kim@summitplc.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Baker&nbsp;&amp; Hostetler LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">45 Rockefeller Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">New York,
NY 10111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Attention: Adam W. Finerman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Email: afinerman@bakerlaw.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">ii. If to any Investor, at its <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address set forth on <U>Exhibit A</U>
to the Purchase Agreement or to such <FONT STYLE="white-space:nowrap">e-mail</FONT> address, or address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Waiver.</U> No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this
Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other right, power or privilege. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governing Law</U>. The provisions of <U>Section</U><U></U><U>&nbsp;8.6</U> of the Purchase Agreement are incorporated by reference
herein <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Integration</U>. This Agreement and the other Transaction Agreements (including all schedules and
exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject
matter hereof, whether written or oral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Headings</U>. The titles, subtitles and headings in this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Counterparts</U>. This Agreement may be
executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the
signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Further Assurances</U>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Contract Interpretation</U>. This Agreement is the joint product of each Purchaser
and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Severability</U>. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or
regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable
manner, and the remainder of this Agreement shall remain binding upon the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)
<U><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></U>. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or
instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by
the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed
on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this
Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SUMMIT THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Manmeet Soni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties have caused this Registration Rights Agreement to be
duly executed as of date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[&#149;]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investor Questionnaire </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d799002dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summit Therapeutics Raises $235 Million </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Fundraise Led by Insiders&nbsp;&amp; Leading Biopharma Institutional Investors in a Private Placement </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>$235 Million in Net Proceeds Raised at Yesterday&#146;s Closing Price of $22.70 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miami, Florida, September</B><B></B><B>&nbsp;12, 2024</B> &#150; Summit Therapeutics Inc. (NASDAQ: SMMT) (&#147;Summit,&#148; &#147;we,&#148; or the
&#147;Company&#148;) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35&nbsp;million shares of the Company&#146;s common stock at
$22.70 per share, the closing price on Wednesday, September&nbsp;11, 2024, for aggregate gross proceeds to the Company of approximately $235&nbsp;million. The capital raise was completed without bankers&#146; fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of Summit&#146;s Section&nbsp;16 officers participated in the capital raise. A total of $79&nbsp;million was raised by insiders, including Robert W.
Duggan, Dr.&nbsp;Maky Zanganeh, Manmeet S. Soni, and Bhaskar Anand, as well as Jeff Huber, a member of the Board of Directors, who invested via a controlled entity. The remaining $156&nbsp;million was raised with multiple leading biopharma
institutional investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summit intends to use the net proceeds to advance, in part, the clinical development of ivonescimab, including in non-small cell
lung cancer and in settings outside of lung cancer by leveraging the data that will be presented at ESMO, which may include, but is not limited to, colorectal cancer, and triple-negative breast cancer, in addition to working capital needs and
general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these
securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Summit has agreed to file a registration
statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock following the closing of the securities purchase agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ivonescimab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivonescimab, known as SMT112 in
Summit&#146;s license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central America, South America, and the Caribbean, the Middle East, and Africa, and as AK112 in China and Australia, is
a novel, potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> investigational bispecific antibody combining the effects of immunotherapy via a blockade of
<FONT STYLE="white-space:nowrap">PD-1</FONT> with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when
in the presence of both <FONT STYLE="white-space:nowrap">PD-1</FONT> and VEGF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This could differentiate ivonescimab as there is potentially higher
expression (presence) of both <FONT STYLE="white-space:nowrap">PD-1</FONT> and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab&#146;s tetravalent structure (four binding sites) enables
higher avidity (accumulated strength of multiple binding interactions) in the TME with over <FONT STYLE="white-space:nowrap">18-fold</FONT> increased binding affinity to <FONT STYLE="white-space:nowrap">PD-1</FONT> in the presence of VEGF <I>in
vitro</I>, and over <FONT STYLE="white-space:nowrap">4-times</FONT> increased binding affinity to VEGF in the presence of <FONT STYLE="white-space:nowrap">PD-1</FONT> <I>in vitro</I> (Zhong, <I>et al</I>, SITC, 2023). This tetravalent structure, the
intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this
design, together with a half-life of 6 to 7 days (Zhong, <I>et al</I>, SITC, 2023), is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g799002dsp55.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III
clinical trials. Over 1,800 patients have been treated with ivonescimab in clinical studies globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summit has begun its clinical development of
ivonescimab in <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), commencing enrollment in 2023 in two multi-regional Phase III clinical trials, HARMONi and <FONT STYLE="white-space:nowrap">HARMONi-3,</FONT> with a plan to
initiate <FONT STYLE="white-space:nowrap">HARMONi-7</FONT> in early 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab
combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic <FONT STYLE="white-space:nowrap">non-squamous</FONT> NSCLC who have progressed after treatment with a 3<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> generation EGFR TKI (e.g., osimertinib). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HARMONi-3</FONT> is a Phase
III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic squamous NSCLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HARMONi-7</FONT> is a planned Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to
pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression <FONT STYLE="white-space:nowrap">(PD-L1</FONT> TPS <U>&gt;</U> 50%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Akeso has recently had positive read-outs in two single-region (China), randomized Phase III clinical trials for ivonescimab in NSCLC, <FONT
STYLE="white-space:nowrap">HARMONi-A</FONT> and <FONT STYLE="white-space:nowrap">HARMONi-2.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HARMONi-A</FONT> was
a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic <FONT STYLE="white-space:nowrap">non-squamous</FONT> NSCLC who have
progressed after treatment with an EGFR TKI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HARMONi-2</FONT> is a Phase III clinical trial evaluating monotherapy
ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression <FONT STYLE="white-space:nowrap">(PD-L1</FONT> TPS
<U>&gt;</U>1%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit&#146;s license territories,
including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Summit Therapeutics</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-,
caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol &#147;SMMT&#148;). We are headquartered in Miami, Florida, and we
have additional offices in Menlo Park, California, and Oxford, UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>https://www.smmttx.com</U> and follow us on X
<U>@SMMT_TX</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact Summit Investor Relations:</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dave Gancarz</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Business&nbsp;&amp; Strategy Officer</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g799002dsp55.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nathan LiaBraaten </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@smmttx.com</U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summit Forward-looking
Statements</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statements in this press release about the Company&#146;s future expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the Company&#146;s product candidates, entry into and actions related to the Company&#146;s partnership with Akeso Inc., the intended use of the net proceeds from the private placements,
the Company&#146;s anticipated spending and cash runway, the therapeutic potential of the Company&#146;s product candidates, the potential commercialization of the Company&#146;s product candidates, the timing of initiation, completion and
availability of data from clinical trials, the potential submission of applications for marketing approvals, potential acquisitions, statements about the previously disclosed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT> equity offering program (&#147;ATM Program&#148;), the expected proceeds and uses thereof, and other statements containing the words
&#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;should,&#148; &#147;target,&#148; &#147;would,&#148; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various important factors, including the Company&#146;s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic,
industry, or political conditions, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including
the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public
health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company&#146;s pipeline of drug candidates, including without limitation, through potential acquisitions of,
and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company&#146;s foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other factors discussed in the &#147;Risk Factors&#148; section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause
delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance
on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company&#146;s views only as of the date of this release and should not be relied upon as representing the
Company&#146;s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. Copyright 2024, Summit Therapeutics Inc. All
Rights Reserved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>smmt-20240911.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 2:46:27 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:smmt="http://www.summitplc.com/20240911"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.summitplc.com/20240911"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20240911_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20240911_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>smmt-20240911_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 2:46:27 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>smmt-20240911_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 2:46:27 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="smmt-20240911.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g799002dsp55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g799002dsp55.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !B * # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***YSXJ
M_%;0_@MX&O?$7B*]2QTVQ7+,>7E;^%$7^)SV'\@":NE3G4FJ=-7;T26[9G5J
MPI0=2H[16K;V2-W4-0@TFQEN;J:*VMH$,DLLKA$C4<DLQX 'J:^3OVB/^"MO
M@[X:S3:?X0MCXNU*/Y3<[S%8QGV;&Z3'L I[-7R)^UK^W9XM_:P\1-IEH9],
M\,>=BSTJW8[ISGY6E(^^_?T7L.I/MW[(/_!)=M:L[;Q!\3C/:Q28DAT.)MDK
MJ1QY[]4_W%^;IDJ017Z9AN$\ORK#K&9_/5[07Y::M][-)=6?E&*XRS/.,2\#
MPY"R6]1_GKHEVNG)]$CRS5/VW_CY^TSKS:?X>NM5B,HXLO#MJT1B!.-V],RX
M]RY%=1X?_P"";WQX^+\4<WBC6UT]'Y8:QJSW$V/HGF'/LQ!K]%O WP]T/X9Z
M%'IGA_2;#1["/I#:PB-2?4XY8^I.2?6MFN&OQW['W,JPT*4>]DW^%E]]_4]#
M#^'?M_WF<8J=:7:[4?QN_NMZ'P?X1_X(UZMHUPL[_$QK"4<_Z'IKL0?][SD_
ME7K'@O\ 8=^(?P\;=I/QY\4(1]U+K3S>0K](I9V3]*^F**\7$\89KB-*TU)=
MG"#7XQ/?PO ^3X;6A3<7W4ZB?X21R_PRT?Q=H6GO;^*M<TCQ!(@'E7=GIK6$
MC^N]/,D7/NN/I74445\Y5J.I)S=M>R27W+0^HI4E3@H1;:7=MO[WJ_F%%%%9
MF@4444 %%%% !1110 4444 0ZAJ$&DV$]U=31V]M;1M+-+(P5(D499B3P  "
M2:_(_P#;V_;!O/VHOBA)'9S31>$]'=H=,MCE?-[&=Q_??'?[HP.H)/U__P %
M;OVAW^&WP<M?!^G3&/4O%S-]I*GF.S0C</;>Q ]"JR#O7P)^R]\(F^.OQ[\,
M^&/G$.I7BBX9,[E@7+RD'L1&KD>XK]?X R:EA\-+.L5V?+Y17Q2]7JO1/N?B
M7B1GM;%8N&18-]5S><G;ECZ+1^K78^SO^"5O[%$&CZ);?$SQ/:++?7?S:%;R
MKD01_P#/R0?XB?N>@&X9RI7Z[^+GQP\&_ 'PJVN>./%?AWPAHRML-[K.HQ64
M!;KM#2, 6]AS71:9IL&C:=;V=K#';VMK&L,,4:[4B10 J@=@  *_G3\5^!]2
M_P""ZO\ P7L\9?#OXB^-=2\.^$O"FHZQIVEV5O(OFP66G2M%]GM$?*+-+L\V
M1BK=)#@A0!^;9YG%;,L7+%5NNR[+HOZW>I^IY!DE#*L%'"4%MN_YI=6_T[*R
M/W+^$W_!1GX"?';Q&FC^$/C%\.=?U>9MD5C:Z];FYF/3"1E@S_\  0:]HK\>
M?VG/^#1+X<ZMX'N)_@_X^\6>'_%-O$6MH/$<L5]87;CHK/%%')#G^^ ^/[AK
M[B^!L;_\$G/^"8VFW?Q?\9>(_&\GP\TA+GQ!JKN^H3AGD4&"WW8=H8C(L:;B
M#L0$XZ#R3VCZDHKQG]A?]N[P'_P4/^#$_CSX=OJ\F@VVIRZ2YU*S^RR^?''%
M(V%R<KB5.<]<^E<+^V%_P5V^$/[#G[0OA;X9>.9?$J>)_&%M;W>GBPTS[1;E
M)[F2VCW/N&#YD39&#@8/>@#Z@HKY@_;O_P""N?PB_P""=/C[PUX;^(LGB9=3
M\5VS75@NF:9]K1D$GEG<=PP=W8 UX_\ M0_\'*7[,_[+WQ>O?!=QJ'BKQCJ6
ME7!M=1N?#6GQ75E92J<.AEDFC$A4\'RMX!!&<@B@#[_HKY/\8?\ !;;]FWP5
M^R?I/QDN/B#:S^%=>E>TT^UMX'?5;JZC"F6V%K@2+)'N7<6PBAT);:Z%O.?V
M1?\ @X^_9N_:^^,&G^!]/O?%7A#7-:N%M-+_ .$ET^*VM]1F8X2))8II55W/
M"B3;N)"@EB 0#[VHKYX_X* _\%._AA_P33T7PS?_ !,DU^.#Q;//;V!TRP^U
MDM"(V??\R[>)%QZ\^E>'_M._\'(7[-?[+^L:7IEYJ'BGQ1JVH6%MJ,]EH&G1
MSOI:3Q+*B7#2RQHLH1QNC5F93PP!H ^]Z*^3_!__  6V_9O\8?LD7GQH'C^W
MT_PEIUT-.NK>]@>/5(+TJ76T^RC+O*R@LNS<I56;=M5B/'?@9_P<_?LO_&WX
MIVGA:2\\9>#SJ%P+:VU3Q#ID4&G.['"[Y(II#$"<?-(JJ,Y8J,T ?H)XC\3:
M=X.T6?4M7U"RTO3K4!IKJ\G6"&$$@ L[$*.2!R>]3V&IVVJZ=#>6UQ!<6EQ&
M)8IXI \<J$9#*PX((Y!%?)__  6H\8_"OP;^Q+-=?%[5/%.D>%9M9M(8;SP_
M;BXN8[HB0QYC)"M&5#@Y/<$<@&OFC]L+]O7X)_ ;_@A#IVF^';_QG/X=^+GA
M#6O#O@VYO+'==SW029&:Y^8")3,QQC("G@8&*[I4L(L&JBJ/VW-9QMHHVT?-
M?>^EK?\ !\^-;%O&NDZ:]CRIJ7-JY7UCRVVMK>__  /U,CF6891E;Z'-.K^>
MG_@W]_X+0?![_@G7^S5XQ\+_ !/N_%AUC7/$QU2U^P:=]LC$'V6"(98N,'<C
M\8Z8]:_H)\-Z_!XJ\.V&J6N_[+J5M'=0[UVML=0RY'8X(KA/0/R:_P""F'Q.
M?XE?M<>(@)-]KH++I%N,_<$/$@_[^F4_\"KL_P#@CIH::I^U'>W+J"=.T.XG
MC)ZJYDACR/\ @,C?G7S?\6_$'_"6?%+Q%JAY.I:E<71/J7D9C^IKW[_@D9XT
MA\-_M<PV,L@5M=TJYL8@3]YQMG_E ?SK^C,VPCH<.U,/2^S3M]RU_4_E[)<8
ML3Q/3Q57[=6_WO3]#]4:_'K_ (*M_P#!M_XL^,7[2&K_ !M_9Z\66OA_Q9K5
MZ=7O]&N[J2P9+XG+W-E=Q@E'D;+E7V@.S$2 $*O[".Q5"0-Q R!ZU^*_B/\
MX.3/C%^Q=^VGXV\+_M#_  8OM*\(W%^S:-IMF$BU+1K5?E5HYS^XOT< ,7#*
M"[-M<+A!_.9_4)XE>?\ !1__ (*,?\$F+BU?XQ:%J_BCP?;S+ \WB:RCU.SF
MYP%&J6I+"1OX?,E8_P"R>17W!^U/_P %#?"__!3+_@WQ^,?Q%\-6D^D3)I9T
MS6-)GE$LNE7L<]LSQ;P '4K(CJ^!E7&0K94>"?\ !3+_ (.9O@C^T5^Q-XY^
M'O@3PIXRUG7?'FD2Z1_Q.[""UM-,64;6G8K+(6DCSN0*,;U4[ABKO_!,W_@F
ME\1[3_@WL^-_AZ]T>^LO%GQ@BN=<T#1IHRES-!#! ;92AY5[AH'V@XRKQ'O2
M ]K_ .#37_E%[J?_ &/6H_\ I+95\F?\'*__ "F8_9[_ .P-HO\ Z>[NN"_X
M(._\%S_!?_!-'X/^*OA7\5] \3C3I-:EUC3[W2K1)I[>=XXX9K:>)WC*C]PI
M4@DY9P0.#7E'_!1[]N34O^"A_P#P5"^$GQ*'A/6/"7@NYGTFP\(QZH@2XU&P
MAU.0/=-@E?FN&N%^4E1Y>W<Q4F@#Z+_X._K-M1_:F^"ENAVO/X>N8U)[$W8
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M)IEB1549Y=B%&>F2>]:=<W\8M LO%'PH\1V&HV-IJ=E<Z;.LMK=0+/#,/+)
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MB9".&/6?"7]F7_A=7[7WA&V^+M_HWQ&F\,_!3P[)J42/]MT7Q'J?V[4%749
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M<_=_2ONDTU='SL<?RZ,YK1[&;3+V*>WDD@GA</')&Q5D8'((/8@@?E7Z8_\
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?=71117XJ?LX4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139764574639056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001599298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Summit Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">37-1979717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Brickell Key Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">203-2034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SMMT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ .38L61PX9>H_ 0  / (   \
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M<F]P<R]A<' N>&UL4$L! A0#%     @ .38L65&Q4.OO    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ .38L
M69E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  Y-BQ9?;[ER&$$   T$0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ .38L
M69^@&_"Q @  X@P   T              ( !I0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  Y-BQ9EXJ[',     3 @  "P              @ &!#P
M7W)E;',O+G)E;'-02P$"% ,4    "  Y-BQ9'#AEZC\!   \ @  #P
M        @ %J$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ .38L620>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ .38L6660>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d799002d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d799002d8k.htm">d799002d8k.htm</File>
    <File>smmt-20240911.xsd</File>
    <File>smmt-20240911_lab.xml</File>
    <File>smmt-20240911_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d799002d8k.htm": {
   "nsprefix": "smmt",
   "nsuri": "http://www.summitplc.com/20240911",
   "dts": {
    "inline": {
     "local": [
      "d799002d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "smmt-20240911.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "smmt-20240911_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "smmt-20240911_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-11_to_2024-09-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d799002d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-11_to_2024-09-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d799002d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.summitplc.com//20240911/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-217618-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-217618-xbrl.zip
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M;6S-9/29.P[SS&=H<FDHGWATBGT9;Y].F>? O^"+2\<1! ]!GXW@=2@U=O]
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M&@8B?B+Y>!(]PN'\>#"4E94)TV]!+?O)$('PVZFO0Q$$8JJ?#(4$T.,GEO]
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M7)D96* A%D=K]I4L562)!INIL$;G9L@FU!W%-=*:Y4R#LLZ]AUAMK,>#O9J
M#OXO&KQ_P<S88BXL2]Z[>YC56C\[5OAS'FL.4W ?U(: V$M2= MYCS<(@RU?
MWQ.O$7F[,>>!P^;*?-3@Z\5%[X;<_-+MGUYWO][T.@,S6>^R4\VEG)X:X$36
M*HAPZE?9$.=FF[U+P#3>,/QQW791U/C%-]*\ 2GI"-[G6?N58'UBXGC%;0M/
M5&$U59N?W*SJPYMO?*G4]RU?7F/,DX)#N=K6+SB7^[%A[[EAV_,?N\GMS,ZR
MM,NB^W!<&PIG!M\GP=0]^1]02P,$%     @ .38L67%VX[32BP  'I8" !$
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M.#(9:81=&A;' Z"70@CWZT04>\D3<1(;JAJ +MWTO*@S<_,$?=$RG7(-[[Y
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M=).DBOC?YZP0L@"[P?UN<7AKG0Y?E7X;[@2B , R)72$D6CCO4#3NJ1'&X\
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M<D^[0=\Y5&E(!1P/*_:L0_[U-/M;8$9<3AZ-UR=)6! ?^YZ/@ZLK$,LDS\2
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M/M.62YI)(2*>.D\CPP+>T:JV-*^^V1 .2X1EU&VWNEPK5-G:&5>9[!Q1$(R
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MKB;XD'+)WBK4;#Q:>P_:R5</5C9OZ3*&O3(.XQB'"\X3>"75@CUG(+37_^(
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M2C-0P4[*TN>L90;CP;]Q6&MX% QB?\ $_?<7,%96JWY^2=?IL[+X$QG;03/
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MZJ?6M>R;C(R.(.(G2TWZ-;6 T'CEUK&+-?;\6W:$/_WN"+_;Z_\AP]G)1[0
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M8&IZ/80WFYM.3.X&NQ,C,7U5#(-P2W!L @"&8,@EQ8!B\%6F070O9?CM+82
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MV1.F1G;SN*M]E6L'N;,9>.[!8N2O)=4*W1.@-VLIC1XR4:$:M+QOCO%.^J-
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M]XNWR:V%H\_ONBBN$(C(^5T.BQ064@4S=H'D3Y4MD*!!!:6PHEN.\UC2]*-
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MRZRWC"L64#'D+X%HM9=CP,!5^S'189I14YAEQI&?DP,AQ18=!;<^_GU=V4^
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MZ!""PZ-HZ\WASLY[,Y?.1[^%JW9[T:HU#W?P^K/YY=ON^W>;_P-02P,$%
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MFQG= 0/X[?7AR>'^Z1-[U_LYX)]SU?=WHP^+B@YT<X,)!X^M64[^  *@/;S
M*P64CQ?*GE9W&WF?Y8H!*<% ^%6*8^1-L\S,8):*W>6S'S$)N@<7\IK8W,_B
MVA+S'Q4PBN(:1X$GX)%S(!*8'U^(Y0*?__?_P9/]Z>G_XKR!R(&4B"=L;EB"
M.*5/%1&8)<I2\-/OGS:P!W.@Y0BF.?T8(S5'ETD!J_KW^[OW]_#N\OA=EH-/
MG>)3'M^!E37+I+1;W-W046+\<ZCAQ6YT!J=5ILMI%AP,3)-(EKGSS4E@45?
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M\]X\(E;;1!:!3M\9FWC7@Z=>U7U;+U;SX)E*0H!H-KA"K?!@)+*VRK)=$#S
M'AW[B5I31?%6T%J798';2GNC!\U]H]]3-7&J3J\ '9.79<)@=-TV-T(GDKG"
M;)_JZ=M9X1OAF:XGA<C6##3)PF=R3N/H^ TZM@V1KBR)T@JTV^4./)83DC^'
MVDN[BW)G0.Q$:UP4&U,99^9=1K*YP8YDV!UGX,@YD#!IV2>0U$6.[X0[T>0X
M ^)U'/90PDW]N#;LN2$A>+TSRV=P.EL_/&XO0)2 [ #Y6\,XUSI.=)%9X14P
MU356E\_LO.%>HONC\0B*[-"\!3(I"A-Y8'8L*O>:.VAO/T6Q>%FT*BTNHF36
MBCU,2_!\A(V9( Q6<<8!64&1:/DQWV),1Z"D)=[1;7TRM)@U)HR+I=C4)//7
MG*6RZJK6/])I&7![Q:=',DOI#1[U6BW%1@&Z1$SK]5DIKF:E+9[MS).\L-:X
MKX IK2ONJ%TQL8,<.'%[Q018+>MHZ\$C.;P+^!,M>'M,0U351#UWA((#?JX0
MV6,7[#CD/ 1OM>+47.0<,-4"^;V3"NQ?H;RJ'M[F;#G)2^JSNIH>QWS+\>N^
MDT'V,L):/F;98ATZ<Z$J.!NW3]KA?;*$\1_M/:8S7!;GM/8AMQ'SJDLX?)J6
M\7N*VAE(Y<;HH<9[-6#H!MN![(U"&\2CP:C."Y_=P:2K*3QMMM9Q*B*QYHES
MU7_IH$HXUZ?H+26+-WJV&/ M=D15I&73CX'M_*?GP)K\LP>1S/R;P_<S=O,Y
M>N%3%4'II[0!*A(7HI!<Y]H@5ZE BG=B7NH+T#--0L-E58#NC=QG)>/F'X :
M//P36%V9U3O5; ?OM/!XP^HI74(RK,C^0 Y%/BSD(GN/'L5VCLP72",D5A3&
M2)BG#D3G*8J'U@3'27PEU8W);,J\>YAKL5:_N2'!L"6;R#:*2WQ1"U*/F[X'
M\[I*/2FZ@NL&]IMRD'O61&/-"?)G6W&3Z8PK8]@YB6V^I+&!/=;+S(\4),[/
M/4MH];!R3*)&BY1RU,)?!$%%3KIU7EZ8M>?MGB<?68RJK O[8YA8@4E]ACM/
M\QI,0_@E'# 9C?9V@!$#SU (,Z:%S?,&#'[<M[M)60 #X-1DI[71\1+]092Z
MSCD%.M_%.J2.1+V^%/,P*NUCDG7JQ*6CSU7Z;,M!/LIFSG'7&C<OL@$O _4H
M#-MT_#:Q<9' )I'[RQXH$1\FH+,1(0&==:8)=,%F-HQV-10QV?)SWW%"'JEC
M:I07& BNA^1P)LXW-AP+\1QR346>!;-;HHAX+IG0XPX*086L=LB+&)-Q%;@1
M6\_4RLIH:^]^KZ?**;6\^9AM1DN<X0U-:DK"]-V G:4.>R"''*1K6ZJT,\[Q
M 63Q'9S-\&9CB*G2(:;5^Q<8E<H!23&GKVVYCJSM)E9K-&"TC@Q/Z6;_6A;K
MR&RU(7I[8W5S0YTH.P_A16'%2S@="E-\0&7R ]5O]9JZ7M+;&><V<X:7E""1
MU<:;_@!##I[C0 *OBP45[*S8%$H(RQ8<$38E*,:>^^K"*R7A]28',<[5-0?)
M'!3R1@NJF6\6K>#MF,//QPD<C5VX0C4!"XI])1B]C>L//.SGZC]@+QMH!=4.
MKV 55XU5 M -7C+FMNL,T;\^O$E;-O>(;G[HPPY>OF(;*2$,%7G0*4&QY_N)
M&I?G QB+4\S$)2ZZOM)M1=/?W'!6@6\4))A6N> T6,Y3N>@4U\Q .5K6%!-?
M+HC#C4QFFP4PW#RE7N\CMT>2SPI@EU@_9DK<)AE\LQUA?" ?BTHA;T0J !MC
MM0EUNK,7BSFTN4&;@]H36 @D5<BI%6T],!I BH+?%TA=*U%G]6 <;2BUA7WE
M-@34MYW[9;FDN[? ++"U%[5W?^>_C(VWI52MMV!GM%@%,H6+_8J/RE.R6DPX
MT6L@.4 & O#>"*8)RTFN;3H018Q<8 2?O@ ;&/=F2)6% RT<8TN9L=E:,$KT
M7< 4"\QH)-4,2P_!+HHR3,O$E][???PW(_-=O9C\:I'DZ6!-UN:&5]=(I&EG
M3TF-(^HDKRYC"[_[*&W%RI-Y>'\':,B<C:&TVNVNN9]XX+JB(%U25-A1F;EI
MXA/LZ)HOBF3ZD>XS6[R>,#VE9$%SD)+9#&*US:F RO-?2.H)W=*&*DFK,FO1
MU$"S/;UV&\?^.K[4SKY-V!XG!X*V)+V2M";+/L)Q_[$L^9+4&:@4,Y;Z?+*8
MT'3-L?]>"@JS?C<W%DF=G,.N7[CP%E$'.BF2YB+036?XVJW'(ZJ^"X]^WC'[
M?(/CI5.=$!B9,Q,GA?*68G%/7GJ%7N&/@W+(\.OW?-JPH-97K(ZH6KLQ1Y9,
MI^B"$#6R%OV:[AS61L+A8YXPVTRT&7UG85D$JJ..%,P)B#0;FZ*L7:P8NMIY
M8\]OMBR*7<SR:%%JH3?"AFF32<7I<7B^;-3Q!'K9!2RM9_Y;I';+MO -++?Y
MY<;HU_%-X[FS_ !U22QWDP)K^]8X>M#+NTQU+(;;I]:>$3^%^=+R'1<!5BZ(
MOK+3<'M@CABL.;<16O20L!)->CC\/__'J-3I-GZ@BH>!*]; EX49$9^BHVN<
MX:&LF65I\N/F6=:2U5I-BOQ</([6'=!;^>'Y'U:$'# [$NUB[Q"0039BM%!\
MO,?M:%QD$DSR)<>JW4EX=]!1._K+1^:7'"N+1O-?>FN6-S<D@!_3$GLHEK;_
MJEH6J:JE-U?99>ZZI(RRN'9LL<5ZV51?N2!C01+K>;_4_':COVJ\Y.&W>,F7
M3I '@B?EG6XGJ>\ZY^(=,60J]6-?T!7%_1(VYRG-#AW3Z#>VOVGR3^WUYL;6
M]T;_1AT%KCVI"*2+B_*5 %U28>8L& $K#"^ R1#IBC:_YZOSXO^#;PO4 /8>
MR)<LZ9B_^1Y8C/>D9)Z00RLL!5S/U>JJ>88\$NA&;);-PKAOD<-)4%NE.$E2
MN8W+#XV6^Y[M@%NG&6L8[-.G,G#@GQ2^00E.;AU:,>EZ.*=&6(,72MC:-SMK
MMP=SJ8NJ0545)F\"%6M4")15N<,!(Z-'!<GHTZPNC=27=<0]KY22=%ZO<<$#
ME=@M4:NM%GFI5"P[JOR2'*U&,>C4^*"Q_\(8^^1T[V2;;6XDIB9VF#)8^G6R
M%II*'<;PT_H)JWC9RH-RS1!3=(L(4V^ B?-2!R),I%TDC=5\WFOR'HL_B?JP
M1@@*[& %\N,Y&90V_-1J G'WCMB\$\Z-L4F6DG;CV\+.:TL%JWT:/TS(FT=H
M.&WIV"LG8N*0&),@/FA',2_=-I2?=04^\RTYPUO>O?/\$G<4(QRL^@;K4+[P
M)+VD7WGVGML;BN=012V51I!CR^FT T2N<DBX, __Z;N-R!$\54FPM/<UEM@5
MUSITHJ(FQL3*.@L:28FZ ^?PC"0M1LE[E<V]QT^CE\MVDB!.S8?G8-_-* 7'
MQ!]MI  N)0=!;&Z3I7A;*X\N_8J3$5SFCW:0>-@NHQ)(N&X$FN1Y+F:!<5Y2
M'3Z)#"X)#TOR%4WX(0#<!;ONX82!+7>K+^!8+ZF(M'.S839BGC!C&T_: E:>
M7E93I!<O&=HE4?GV2__^J9EN<[(O,=;&-V5XJTH0*JD'5V:+EF!!*E(5)(,;
M![LE8<VPT%W'L9MAMQ<YH#C&9;WUY!-<XU:!_@0&5:KHKD-D>-K9?%&8-/@Q
M 9>C?_ 2]%PLRT(T*Q0Q=B3K12S=9[Q37"^+'NT,-F5F3H)0"&H#=>%<S4#)
M'FEQ>A!-O230BM"%E?>?RJX,?3:4IN:\8B9NBU9RD9T38@]ES,>1$?IF!.,=
MEBKB."AYP/AXDV7=)&V$VDBXD+CK+5ME[<[(AM5UAP0$1^49I KRY4=+GRK;
M*\J;G"ZELLV[(WYB/7QB5F19$6UW9:LWQ-]DQ%^SG!BD#.(?!BP"AO9="9R0
M@YX0WL'N %)M[SD?\D;VR3&&\#6V!D#?4X<PUBEUD+( ]+8%:G@,1-<L\G[_
M_Q#[D<J63J(58P )5-#Z9^K.949)'"C4"\((:]V9]+%,RUOJ; YDQZ!]8_>7
MJ]3%MSW*#D/\-="#7H!,B[HP;YS:H)D3(TBY<F48/9^VUM#4:6\"U=')S7.E
M5R-3E%(7W#JT"85YT_8U9'[T'&G?L:DDN!ZQ-@IG=O@2O6)N@0/*K!)[O5HM
M<DV4+[[<&9 UPM3R\8*JM;177TFU<EINAF>S*D67+RV*KL84']&(?21*3+6L
ME.=1.1Y;592M-)?@F#OS'%=T^DKXC!15+C;2QA0%83BB0H +IP3X;R4M8'-C
M5 U8[VA,P,:Y ZW/4'8R5-)M^1>]?7LWVB_7*"R8+ML=5D3%B)ASO9=<.B<1
M/U<<.08-_R%E3".5JLQU*5CG&!OKE*Z4 !_'LBNJ,JP;Z\\?O_P=JDC" ^/1
M@;T3 &UF:\+,B>M[*]FL= :&CW!<D*H<JCI<D?/R(K,C$=?C%_9C.HU96<!-
M-5E2/#OQTZ-PMT1ESU0T+]!PZ?%P9+PJTVE5IX[CX8@=OA7Y!?6]8VW9"09<
M4 T4G:E(62?6]0KE$Q4]J(J4X6>#2?7L7*SU>M\V68N.B8@#<)A 8.B0">W?
M7]7E_NB;R_UV)0I!A,R Z(7%T$$E71AVZUJVO:FC R/VY";9L):X5TU(T %-
M.YQ1=@/VA8S=W7$@&*R^FV3YY!S3Y"?AK>QC%4_116*4"=9QX0-1@HS.F[1!
MK0<8B=TLGJ!>ES*D1YQ3H35A9K>YH3F9B[R1THZ!AJV]^\]./_3@=?SP^&]/
MHTO$FIHFQ0[1VQ/"F6@OGGT'3SS?[DF3'>=J!M]PW45;4W5@T3XMA,O?W @9
MN;=\3)6U^;^/']]J$W(P%U.$62NNUV3QG^7 NRVZ[,/=Z.3PS?[9X4'T\MW;
M]_O'OT?O7@#WV6>TV57- M;Q*]YX6K_UQ.!'N I"$U$B\HC>G-0^4B(%D)6J
MMY9TU!X'JS>N"JZ)OV LW[=K*:R163^B_8QHBET=B-D@)>.AM3//P%0B5[8N
M-56>-PTS;G#W!TP=NE*6%RC&_SDPRK<%@:$3/J:D=D93Y!1FKT*64@Q#WV1@
M'IAO99])S! X%F<A&? I/[=R_3CL&)UPC):"R6L@=\0VBW=SHP<I0ZHP^#=!
MN04:R'BVA'3* -LV(UC04ELI+[$0Z&[E/E*)1N=RHP@TF* 9EA860A<0F/S#
M$1B48<X0<UW>2(*UR6[T(#KHG2DW)D@\#(N[P$NF/ 9;XT<9#'WTV@,/Q+>:
MS_G:@[ ;1+?KE!"N0[;Q"J(UN]P+[Z<MK5C\+#:4.8"'1_7I(UKAYH9;FXE_
M^!GQDN'GW+H6]*3/<.JM4Z=!#6HO?MB7-9;B[/+)<NVH2U@"3HGM-GR9&^^@
ME0A^AH &8S%SM$D#?9M)E YKI;$&@%62*6A>!FZ@7H4K%Y8;WUFMI75[G% H
M8H#1>V ^G\]D1JA_<Z/#9&[.Q0>!^.)1EQ"3/GQ1-HGX-;SHED BB!_(9LOX
MTFX418L8.4?54_%DS+ B(V5RK!;H7%^65(S8"X3%6D7IX+@PGK6UUY.,Z,"?
M>G"G.,3^0BV@1Q<YQ^NO;T^Z##I*.!3_N4H+H01-$(&7M@^0[_NJ_?W9%=B&
MKUZA]9*11O9-2?  S2N,-<^]?G6!J1HCRO-8;I<&OS)FOJ$7AX"RKC!1 KEU
M[O&M(9#1=9#+@F%#V"U3"#PNR0QJII*8:#=\"=6.0R%)G?5!FDF&<X<+F5S[
M<?15@Z4M!^_29M70!J\9A[,S23%UVV15!9N,_I_N+E,0G^&A;7QE(-BMH!K,
M7(1A-2UP$2MZL<:,@,-QZ!PVB[&Q:Q2U%5Z8:>9NY>@H!E..<KLT2QWS,&TI
M7DWJ9%@*P^X*@4UHO,RD657W>#,NJ))YB5%V>&I&D-E(.2UPII8*T3@8@),2
MQ!][H$GC[BO'^$)0M8@RWB2:-$NFV'?$E'.MC=<:55<E7R47X[)4H9#_1S8N
MV.[5U=L.$C$,8)N5"=P3_>8?:'VZPGHOT($;T^G7UK-5:[KE^'YW Y23S'?%
M&=P[!:H8RNL )L$'-\PUF@,6<1[\LG_RUTUI?_S-O_XGI+1K[P55G6,-[#N\
M[\W3Z*W)J'Q)9DF/=\.YEK0O"2B\THE9#F^$NJ&44YOI[4IN'1Z92L#NM*(A
M9Y'+A,@E+,<C(/8(>1) (9X0Z R^$J556B=7G#]OZ[KX$<5&O+3'[AI[4SU=
MMBQ#;6QNV*HL57OWX%%$2'';*BA+G+J6;!(<F]'<+12"9G8*(JR_YY]QJ'!]
M0.ZVM\<#XN7FS[*4NHE6M61"^TV=3/,-=F$X:T8Z0'DFS1@R[XA?!,VD7M_(
M4W7,-UBU1V2W77:72*5@090GY1BX674$; 2!_9,/,QQUH!+"@YY1>Q^OU@7I
M)RLW$<<H W9 BH^^CYL;7ON8%6+?ZTQEC'W1]O^ 'S6IQ"U$QV+X$_.)9UOJ
MK^S>8!VBZ8#%&B?WD^/&7@I](= 1R3M)ZBVUXI5O+Y(%+-0$'14()*I<FQMS
M2BEF@ABI+J!<NO$4FNYUD+(%J]_9'!F<%[Q83<I<%_*FX2XQ;[8X_5X-0OEY
MTU$ZW^;&BAH)<\E\E];JR@FM5PY@=)G\1WE\*ZBE"+T@GUM,L1T44\AU88ZF
MT(\J 9NZT5;V^ -[\=Z$-17)U0#V::@?ZF((7RKQI9WPPBEU!=OOP)45G=6"
MA\H^<6&["VAC9ZIH6E#-J4-AJ?@^62:K8I$+Y"(I=Y_#H ^\=0NEEP>$=>K8
MR"&^T$-F0/$)FWF!-C.OF$HX!Y=LTOQ8UJ(%1"";\+NABH!X7 1L;@S( )X-
M=P8>%0;=2KEQ.OFR,N"SXGVL)3&=^VJ25I%"_&9E8^$&]Y'K$.R^ UP$KE6?
M(WR;Q>%G/]EGF.&?)=IY9JY'457+9@$M(Q$G>)!]'4N^1.3"<]T.'*E)4B-F
MQX[V(+V:9$]XJ_S^Y_82!X(0HW>8"6BOJR1TK2CU?@A&@TNI]IR AMK6J9F@
MRBOXVEYG!Z^Q#JJ=E]!)J*02%S99[91^2K6$KN+*%=?[1]*(VZ,!FWE-^]W
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MZ=*GK8]>?^8:)P^#I<(9>Q)JJJYKU)8+J"861[+9R'IY&E[N#$G=AMW_1=7
ME81U.[L\QMSG? XK%PB^."IRCNN29<$:#&S.E/[\8YF>"Y@-NM=QAZE+(_^6
M<M7I(>R+TI.4Z*7M3#%^*[]E: KIIJ)$7*P-+*(>\2I3/F2+7.':M":<T>&Z
M-H'<(PX4N[801) M)45S+IPR",2*JF,/3)C3-LG/M"R5W";HX:Q(8Q<AY*X%
MTL! </R')B^@[>AQ]G&=Y5P_/'])YT*N.S[+;:TV:(:>$VW1@>)>\_9QN01V
MKYUEMN^;)-+(H>-"<\JV0/?T=:PJQ6(]*,>%L>B+HH<?L]*IB^@X.*]P>(8;
M8%>"%"G@^<)GNK0 #B@%I5($#N-=24"#';?HTL'+..7AJO3:7 0J8C!IJJ8&
MA+[# OZLQ'I6E\6*)::$%IVK^X'L@& -I5H=423E0Q/=W>J]6+;SLNZ2JL'?
MF83F,BIA>MD(;-E4L\0! _/!4GS/Y#5Q<8/L?>.687K%I.$Z58JSQ(VV(^HU
M'U'JKU2>UB01L:4;6$PJ]L:QE[ !$ 5RLG/N -?YKC)0^^IW[C/6/OW*-X%F
M6-V3BDL],N0-):9QO??+7S%C3WUF"UDT;!"VR/*!13!QC8/-:M&7>54X@I95
MN \##=S$VU@Q/5U.FAQLNUIAJH1Y2W["HP[7<9&-GPW!WTAG"LF,D#0:DQ_1
MB<_GI2FS' &,H6P,)IJ!T,A?U0?ZXS<?Z.W @P?2Z'PLW> 2(/6S?B21#:?1
M)[8L&6XI_SN(]H[9L^*17#M#DWO;FN8ESK,F$HBKN!K-YU).AB'<>I34/9+V
MQ?-?#0/0_'W0ZUMG^7P"1E)F(M"A^N6Y8KEDRQA#@N;$DIM4RYK1L/#?TM@X
M#HH[:!,X[ KFU7#@=65D%B3#3C7;6533CUEKL] XY,NM9E"#T@)YE?+BUL*<
M<]YWR)YVP@J2UDB<2)0=#]K58@Q9^M6V?@-:)6!,$SG\VLI[R6!+K/WJ":0U
MLI:^EXZM3S K0+>R7BPX!2'AB=M:I XEH$BF52\-&H23Q_"T)3Q1)*@VMR&G
M"8I#BK3Q3TMCN:,?&5,N96L5YI$%F?);-N@KV+&?*]L!HC-U4PM-'C JF6NR
M-1I*J"QPJBHB9Q?F1!F"7Z#OW)]EMZ'QR+R ]D#S:?Q)K7*4C189=S#*JMI1
M9J< (,0H-#B\)M?6*[O+9P&+POVPR3,I-H*T^6&^\O'4I82$ )=2I8#=G=(
MUE.W>ES6EI=+EIF7["#;28H\6*NLS1NR!3.14E>"&ZJ:4(\%Y0U@%>59B!)L
M=F^KJBT(2C MXTT-CWS;;..X6CH;4S]Y*CU[1B="Y=33UOT42;;I0J:VA#4L
MM2L>':!.GEBO1H=HX24L>EDL"&ZCN@)B9)IX(? +PL6/B5E:8&""@J/ MEJ
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M1A5]2:,0UJR.U-F*.Z!*[A-_2E"*7#;(5'@TL_LLI>9RX%TYE>..%YA[+23
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MP]<NUNP8:8@'$E?B!Q/0F2,M]RM,; E]QIJE2>1D4"84B]B\BB-:>H?'OR.
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M<&QT1\D(^-BF^UZ\KBM)%6A30:E5*%J_N#XZ.]KH<)(,/T (J S5\7A1+$*
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M@]3<Z0+SZ.OFB'DS#W+JDB]02P$"% ,4    "  Y-BQ95-Y.X: 7  #(C
M#@              @ $     9#<Y.3 P,F0X:RYH=&U02P$"% ,4    "  Y
M-BQ9<7;CM-*+   >E@( $0              @ ',%P  9#<Y.3 P,F1E>#$P
M,2YH=&U02P$"% ,4    "  Y-BQ9J6_8A!]#  #G,0$ $0
M@ '-HP  9#<Y.3 P,F1E>#$P,BYH=&U02P$"% ,4    "  Y-BQ9>',9MP84
M   Y0P  $0              @ $;YP  9#<Y.3 P,F1E>#DY,2YH=&U02P$"
M% ,4    "  Y-BQ98@P';3\#  !/"P  $0              @ %0^P  <VUM
M="TR,#(T,#DQ,2YX<V102P$"% ,4    "  Y-BQ9JDJ@CGH&  "Y1@  %0
M            @ &^_@  <VUM="TR,#(T,#DQ,5]L86(N>&UL4$L! A0#%
M  @ .38L65Y_M%K"!   02P  !4              ( !:P4! '-M;70M,C R
C-# Y,3%?<')E+GAM;%!+!08     !P ' +X!  !@"@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d799002d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="smmt-20240911.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-11_to_2024-09-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2024-09-11</startDate>
            <endDate>2024-09-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-328">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-11_to_2024-09-11"
      id="Hidden_dei_EntityCentralIndexKey">0001599298</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-339">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-340">2024-09-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-341">Summit Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-342">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-343">001-36866</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-344">37-1979717</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-345">601 Brickell Key Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-346">Suite 1000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-347">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-348">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-349">33131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-350">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-351">203-2034</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-352">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-353">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-354">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-355">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-356">Common stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-357">SMMT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-358">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-11_to_2024-09-11" id="ixv-359">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
